avir20161231

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

0001437749-17-001767.txt : 20170206 0001437749-17-001767.hdr.sgml : 20170206 20170206150856 ACCESSION NUMBER: 0001437749-17-001767 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170206 DATE AS OF CHANGE: 20170206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aviragen Therapeutics, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 17575365 BUSINESS ADDRESS: STREET 1: 2500 NORTHWINDS PARKWAY, SUITE 100 CITY: ALPHARETTA STATE: 2Q ZIP: 30009 BUSINESS PHONE: 301-770-3099 MAIL ADDRESS: STREET 1: 2500 NORTHWINDS PARKWAY, SUITE 100 CITY: ALPHARETTA STATE: 2Q ZIP: 30009 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20020304 10-Q 1 avir20161231_10q.htm FORM 10-Q avir20161231_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended December 31, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from to .

Commission File Number: 001-35285

Aviragen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

59-1212264

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

2500 Northwinds Parkway, Suite 100, Alpharetta, GA 30009

(Address of principal executive offices, including zip code)

(678) 221 3343
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of” large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock, par value $0.10 per share at February 6, 2017 was 38,649,237 shares.

Table of Contents


PART I: FINANCIAL INFORMATION

Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of December 31, 2016 (unaudited) and June 30, 2016			3

Condensed Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2016 and 2015 (unaudited)			4

Condensed Consolidated Statement of Stockholders’ Equity for the Six Months ended December 31, 2016 (unaudited)			5

Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2016 and 2015 (unaudited)			6

Notes to the Condensed Consolidated Financial Statements (unaudited)			7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			14

Item 3. Quantitative and Qualitative Disclosures About Market Risk			20

Item 4. Controls and Procedures			20


PART II: OTHER INFORMATION			21

Item 1. Legal Proceedings			21
Item 1A. Risk Factors			21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			23
Item 3. Defaults Upon Senior Securities			23
Item 4. Mine Safety Disclosure			24
Item 5. Other Information			24
Item 6. Exhibits			24
Signatures			25

Exhibit Index			26

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

Aviragen Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in millions, except share amounts)

	December 31, 2016			June 30, 2016

ASSETS
Current assets:
Cash and cash equivalents	$	38.1		$	49.7
Short-term investments		11.1			19.3
Accounts receivable, net of allowance		4.2			0.7
Prepaid and other current assets		2.8			2.7
Total current assets		56.2			72.4
Non-current assets:
Property and equipment, net		0.3			0.3
Total assets	$	56.5		$	72.7

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3.4		$	3.9
Accrued expenses		5.6			3.6
Short-term note payable		0.3			0.4
Liability related to sale of future royalties, current portion		1.2			1.3
Total current liabilities		10.5			9.2
Non-current liabilities:
Long-term note payable, net of current portion		0.2			0.3
Liability related to sale of future royalties, net of current portion		17.6			16.8
Other long-term liabilities, net of current portion		0.2			0.2
Total liabilities		28.5			26.5

Commitments and contingencies		-			-
Stockholders’ equity:
Preferred stock, $0.10 par value: 5,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock, $0.10 par value: 200,000,000 shares authorized; 38,640,487 shares issued and outstanding at December 31, 2016 and June 30, 2016		3.9			3.9
Additional paid-in capital		158.5			157.6
Accumulated other comprehensive income	19.0			19.0
Accumulated deficit		(153.4	)		(134.3	)
Total stockholders’ equity		28.0			46.2
Total liabilities and stockholders’ equity	$	56.5		$	72.7

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aviragen Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(unaudited)
(in millions, except share and per share amounts)

	Three Months Ended December 31,						Six Months Ended December 31,
	2016			2015			2016			2015
Revenue:
Royalty revenue	$	1.5		$	1.7		$	1.6		$	3.4
Non-cash royalty revenue related to the sale of future royalties		2.3			-			2.3			-
Total revenue		3.8			1.7			3.9			3.4

Operating expense:
Research and development		10.2			6.3			17.8			11.8
General and administrative		2.1			2.1			4.3			4.4
Foreign exchange (gain) loss, net		0.1			(0.2	)		-			0.5
Total operating expense		12.4			8.2			22.1			16.7
Loss from operations		(8.6	)		(6.5	)		(18.2	)		(13.3	)
Other (expense) income:
Non-cash interest expense on liability related to sale of future royalties		(0.5	)		-			(0.9	)		-
Interest income		0.1			-			0.1			0.1
Total other (expense) income		(0.4	)		-			(0.8	)		0.1

Loss before tax		(9.0	)		(6.5	)		(19.0	)		(13.2	)
Income tax expense		0.1			-			0.1			-
Net loss	$	(9.1	)	$	(6.5	)	$	(19.1	)	$	(13.2	)


Basic and diluted net loss per share	$	(0.24	)	$	(0.17	)	$	(0.49	)	$	(0.34	)

Basic and diluted weighted-average shares outstanding		38,640,487			38,636,946			38,640,487			38,630,587

The accompanying notes are an integral part of the condensed consolidated financial statements.

Aviragen Therapeutics, Inc.

Condensed Consolidated Statement of Stockholders’ Equity
(unaudited)
(in millions, except for share amounts)

	Common Stock									Accumulated
	Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Other Comprehensive Income		Total Stockholders’ Equity
Balances at June 30, 2016		38,640,487	$	3.9	$	157.6	$	(134.3	)	$	19.0	$	46.2
Net loss		-		-		-		(19.1	)		-		(19.1	)
Share-based compensation		-		-		0.9		-			-		0.9
Balances at December 31, 2016		38,640,487	$	3.9	$	158.5	$	(153.4	)	$	19.0	$	28.0

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aviragen Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)
(in millions)

	Six Months Ended December 31,
	2016			2015


Cash flows from operating activities:
Net loss	$	(19.1	)	$	(13.2	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		0.9			1.2
Non-cash interest expense related to sale of future royalties		0.9			-
Non-cash royalty revenue related to sale of future royalties		(2.3	)		-

Change in operating assets and liabilities:
Accounts receivables		(1.4	)		7.5
Prepaid expenses and other current assets		(0.1	)		(0.9	)
Accounts payable and accrued expenses		1.4			(2.8	)

Net cash used in operating activities		(19.7	)		(8.2	)

Cash flows from investing activities:
Purchases of short and long-term investments		(8.4	)		(6.4	)
Maturity of short-term investments		16.6			9.0

Net cash provided by investing activities		8.2			2.6

Cash flows from financing activities:
Payment on note payable		(0.1	)		(0.1	)

Net cash used in financing activities		(0.1	)		(0.1	)

Decrease in cash and cash equivalents		(11.6	)		(5.7	)
Cash and cash equivalents at beginning of period		49.7			44.7

Cash and cash equivalents at end of period	$	38.1		$	39.0

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

1) Company Overview

Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has four Phase 2 clinical programs: vapendavir, an oral treatment for rhinovirus (RV) upper respiratory infections in moderate-to-severe asthmatics; vapendavir, for the treatment of RV infections in hematopoietic stem cell transplant patients; BTA585, an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus ("RSV") infections; and BTA074, a topical antiviral treatment for condyloma caused by human papillomavirus types 6 & 11. The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia.

Although several of the Company’s influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any product candidates that it is developing now, or may develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates.

The Company plans to continue to finance its operations with (i) existing cash, cash equivalents and investments, (ii) proceeds from existing or potential future royalty-bearing licenses or collaborative research and development arrangements, (iii) future equity and/or asset or debt financings, or (iv) other financing arrangements. The Company’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources, continuing to receive royalty revenue under existing licenses, entering into future collaboration, license or commercialization agreements, the successful development of its product candidates, executing future financings and ultimately, upon the approval of its products for sale and achieving positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to the Company, if at all, that the Company will be able to enter into collaboration, license or commercialization agreements in the future, or that the Company will ever generate significant product revenue and become operationally profitable on a consistent basis.

(2) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the condensed consolidated financial statements included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 13, 2016.

The unaudited interim condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation.

Operating results for the three and six months ended December 31, 2016 are not necessarily indicative of those in future quarters or the annual results that may be expected for the Company’s fiscal year ending June 30, 2017. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2016 included in the Company’s Annual Report on Form 10-K.

The Company’s significant accounting policies have not changed since June 30, 2016.

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

Recent Accounting Standards

In May 2014, the Financial Accounting Standards Board ("FASB") issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.

In August 2014, the FASB issued authoritative accounting guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for annual reporting ending after December 15, 2016, and for annual periods and interim periods thereafter, with early application permitted. Accordingly, the standard is effective for the Company on June 30, 2017. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In January 2016, the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements.

In February 2016, the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements.

In March 2016, the FASB issued guidance on stock compensation. This guidance simplifies the accounting for the taxes related to stock based compensation, including adjustments to how excess tax benefits and a company's payments for tax withholdings should be classified. The guidance is effective for public companies for annual periods, and interim periods within those annual periods, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact that the guidance will have on the consolidated financial statements.

In August 2016, the FASB issued new guidance on how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for the Company beginning July 1, 2018. Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

In January 2017, the FASB amended and clarified guidance related to business combinations and the definition of a business. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Accordingly, the amendments are effective for the Company beginning July 1, 2018. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

(3) Fair Value Measurements

A fair value hierarchy has been established that requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes three levels of inputs that may be used to measure fair value:

	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at December 31, 2016 and June 30, 2016, by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company’s short-term investments have been classified as Level 2, which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a third party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications.

			Quoted Prices in		Significant
			Active Markets		Other		Significant
(in millions)			for Identical Assets		Observable Inputs		Unobservable Inputs
December 31, 2016	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	10.7	$	7.7	$	3.0	$	—
Short-term investments available-for-sale		11.1		—		11.1		—
Total	$	21.8	$	7.7	$	14.1	$	—

			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for Identical		Observable		Unobservable
(in millions)			Assets		Inputs		Inputs
June 30, 2016	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	1.5	$	1.5	$	—	$	—
Short-term investments available-for-sale	19.3			10.0		9.3		—
Total	$	20.8	$	11.5	$	9.3	$	—

Cash equivalents consist primarily of money market funds. Short-term investments consist of certificates of deposit, corporate securities, U.S. Treasury securities and U.S. agency securities, classified as available-for-sale and have maturities less than 365 days from the date of acquisition.

The following table shows the unrealized gains and losses and fair values for those investments as of December 31, 2016 and June 30, 2016 aggregated by major security type:

(in millions)			Unrealized		Unrealized
December 31, 2016	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	7.7	$	-	$	-	$	7.7
Corporate notes		9.4		-		-		9.4
Commercial paper		3.0		-		-		3.0
Certificates of deposit		1.7		-		-		1.7
Total	$	21.8	$	-	$	-	$	21.8

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

(in millions)			Unrealized		Unrealized
June 30, 2016	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	1.5	$	—	$	—	$	1.5
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		7.0		—		—		7.0
Corporate notes		2.9		0.1		—		3.0
Certificates of deposit		7.3		—		—		7.3
Total	$	20.7	$	0.1	$	—	$	20.8

As of December 31, 2016, the Company had no investments in an unrealized gain (loss) position. As of June 30, 2016, the Company had investments in an unrealized gain position. The Company has determined that the unrealized gains on these investments are temporary in nature and expects the security to mature at its stated maturity principal. All available-for-sale securities held at December 31, 2016, will mature within a one year period. The fair value of cash, accounts receivable, accounts payable and accrued liabilities approximate their carrying value because of the short-term nature of these financial instruments respectively, at December 31, 2016 and June 30, 2016. The fair value of the Company’s short-term note payable, which is measured using Level 2 inputs, approximates book value, at December 31, 2016 and June 30, 2016.

(4) Accrued and Other Current Liabilities

Accrued expenses consist of the following (in millions):

	December 31, 2016		June 30, 2016

Professional fees	$	0.5	$	0.1
Salary and benefits		0.5		0.6
Research and development expenses		4.6		2.2
Other accrued expenses		-		0.7
Total accrued expenses and other liabilities	$	5.6	$	3.6

(5) Liabilities Related to Sale of Future Royalties

In April 2016, the Company sold certain royalty rights related to the approved product Inavir^®, sold by Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in the Japanese market, for $20 million to HealthCare Royalty Partners III, L.P. (“HCRP”). Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the arrangement, this transaction was accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. As of December 31, 2016 and June 30, 2016, the amount receivable from Daiichi Sankyo related to the HCRP transaction was $2.2 million and $0.2 million, respectively, which has been included in “Accounts Receivable” in the accompanying condensed consolidated balance sheets.

In order to record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement with Daiichi Sankyo and the payments that will be passed through to HCRP over the life of the agreement. The sum of the pass through amounts less the net proceeds received will be recorded as non-cash interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The Company will periodically assess the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company will adjust the amortization of the liability and interest rate. As a result of this accounting, even though the Company does not retain HCRP’s share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability and related interest is fully amortized.

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

The following table shows the activity within the liability account during the six months ended December 31, 2016:

	(in millions)
Total Liability related to sale of future royalties, June 30, 2016	$	18.1
Non-cash royalty revenue paid to HCRP		(0.2	)
Non-cash interest expense recognized		0.9
Total Liability related to sale of future royalties, December 31, 2016	$	18.8

(6) Net Loss per share

Basic and diluted net loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and unvested restricted stock units) are excluded from the calculation as their inclusion would be anti-dilutive. The Company has excluded all anti-dilutive share-based awards to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following tables set forth the computation of historical basic and diluted net loss per share.

	Three Months Ended December 31,
	2016			2015

Net loss (in millions)	$	(9.1	)	$	(6.5	)
Weighted-average shares outstanding		38,640,487			38,636,946
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,636,946
Basic net loss per share	$	(0.24	)	$	(0.17	)
Diluted net loss per share	$	(0.24	)	$	(0.17	)
Number of anti-dilutive share-based awards excluded from computation		5,645,543			4,631,556

	Six Months Ended December 31,
	2016			2015

Net loss (in millions)	$	(19.1	)	$	(13.2	)
Weighted-average shares outstanding		38,640,487			38,630,587
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,630,587
Basic net income (loss) per share	$	(0.49	)	$	(0.34	)
Diluted net loss per share	$	(0.49	)	$	(0.34	)
Number of anti-dilutive share-based awards excluded from computation		5,645,543			4,619,210

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

(7) Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GlaxoSmithKline (“GSK”) in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as Relenza® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and has been entitled to receive royalty payments of 7% of GSK's annual net sales of Relenza^® in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of Relenza^® in Australia, New Zealand, South Africa and Indonesia. Most of the Company’s Relenza^® patents have expired and the only substantial remaining intellectual property related to the Relenza^® patent portfolio is scheduled to expire in July 2019 in Japan.

The Company also generates royalty revenue from the sale of Inavir^® (laninamivir octanoate or LANI) in Japan, pursuant to a collaboration and license agreement and a related commercialization agreement (collectively, the “Inavir License Agreement”) with Daiichi Sankyo. In September 2010, Inavir^® was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children. Under the Inavir License Agreement, the Company currently receives a 4% royalty on net sales of Inavir^® in Japan and is eligible to earn sales milestone payments. Under the Inavir License Agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. Patents on the composition of matter for LANI in Japan generally expire in 2024.

In April 2016, the Company entered into a Royalty Interest Acquisition Agreement (“Agreement”) with HCRP. Under the Agreement, HCRP made a $20 million cash payment to the Company in consideration for acquiring from the Sellers certain royalty rights (“Royalty Rights”) related to the approved product Inavir^® in the Japanese market. The Royalty Rights were obtained pursuant to the Inavir License Agreement.

The following tables summarize the key components of the Company’s revenues (in millions):

	Three Months Ended December 31,
	2016		2015
	(in millions)
Royalty revenue - Relenza^®	$	1.5	$	1.0
- Inavir^®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.8	$	1.7

	Six Months Ended December 31,
	2016		2015
	(in millions)
Royalty revenue - Relenza^®	$	1.6	$	2.7
- Inavir^®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.9	$	3.4

Collaborative and contract arrangements

In July 2016, the Company entered into an exclusive, worldwide license for RSV replication inhibitors intellectual property with Georgia State University Research Foundation (“GSURF”) in exchange for an upfront fee, future milestone payments and royalties on future net sales of any products that utilize the underlying RSV intellectual property. The Company has an obligation to make a minimum payment of $10,000 to GSURF annually until the license agreement expires or is terminated. The Company also entered into a two year sponsored research agreement with GSURF for annual sponsored research payments.

Aviragen Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements (unaudited)
(for the period ended December 31, 2016)

In connection with the Company’s BTA585 clinical trial, a Clinical Research Organization (“CRO”), engaged by the Company to provide certain services for this trial, notified the Company of its intent to explore additional compensation due to a previous delay in the trial. In December 2016, the Company and the CRO agreed to a settlement and the Company’s insurance carrier agreed to reimburse the Company for the amount of the settlement, less its deductible.

(8) Share-based Compensation

On November 10, 2016, our stockholders approved the 2016 Equity Incentive Plan (“2016 Equity Plan”), under which a total of 4,794,137 shares may be available for issuance. The 2016 Equity Plan replaced and superseded our amended 2007 Omnibus Equity and Incentive Plan (“Prior Plan”). In addition, under the 2016 Equity Plan all outstanding awards under the Prior Plan will become available for issuance under the 2016 Equity Plan if such awards are forfeited or otherwise terminate.

For the three month period ended December 31, 2016 and 2015, the Company recorded share-based compensation expense related to grants from equity incentive plans of $0.5 million and $0.6 million, respectively. For the six month period ended December 31, 2016 and 2015, the Company recorded share-based compensation expense related to grants from equity incentive plans of $0.9 million and $1.2 million, respectively. No income tax benefit was recognized in the statements of operations and no share-based compensation expense was capitalized as part of any assets for the three month and six month periods ended December 31, 2016 and 2015.

ITEM 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In most cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “forecast,” “potential,” “likely” or “possible”, as well as the negative of such expressions, and similar expressions intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to:

●	our anticipated timing to report top line-data from our Phase2b SPIRITUS clinical trial for vapendavir;
●	the information that we will file with respect to our interaction with the Food and Drug Administration regarding its clinical hold for BTA585;
●	our timing to initiate our Phase 2 trial of vapendavir for the treatment of RV infections in HSCT patients;
●	our anticipation that we will generally incur net losses from operations in the future due to our intention to continue to support the preclinical and clinical development of our product candidates;
●	our future financing requirements, the factors that may influence the timing and amount of those requirements and our ability to fund them;
●	the number of months that our current cash, cash equivalents and anticipated future proceeds from existing royalty-bearing licenses and other existing license and collaboration agreements will allow us to operate; and
●	our plan to continue to finance our operations with our existing cash, cash equivalents and proceeds from existing or potential future royalty-bearing licenses, or collaborative research and development arrangements, or through future equity and/or debt financings or other financing vehicles.

Various important factors could cause actual results, performance, events or achievements to materially differ from those expressed or implied by forward-looking statements, including the U.S. Food and Drug Administration (“FDA”) or a similar regulatory body in another country, a data safety monitoring board, or an institutional review board delaying, limiting, suspending or terminating any of the Company’s clinical development programs at any time for a lack of safety, efficacy, tolerability, anti-viral activity, commercial viability, regulatory or manufacturing issues, or any other reason whatsoever; the Company's ability to secure, manage and retain qualified third-party clinical research, preclinical research, data management and contract manufacturing organizations upon which it relies to assist in the design, development, implementation and execution of the clinical and preclinical development of all its product candidates; and these third-party organizations fulfilling their contractual obligations on a timely and satisfactory basis; the safety or efficacy data from planned or ongoing future preclinical and clinical studies of any of its product candidates not supporting the clinical development of that product candidate; the successful enrollment of the requisite number of study participants on a timely basis; the Company’s ability to comply with applicable government regulations in various countries and regions in which we are conducting, or expect to conduct, clinical trials; the Company’s ability to retain and recruit sufficient staff, including key executive management and employees, to manage our business; the Company’s ability to maintain, protect or defend its proprietary rights from unauthorized use by others, or not infringe on the intellectual property rights of others; our ability to successfully manage our expenses, operating results and financial position in line with our plans and expectations; the condition of the financial equity and debt markets and our ability to raise sufficient funding in such markets; changes in the general economic business or competitive conditions in the industry or with respect to our product candidates; and other cautionary statements contained elsewhere in this Quarterly Report on Form10-Q and in the Company’s Annual Report on Form 10-K for the year ended June 30, 2016, as filed with the U.S. Securities and Exchange Commission on September 13, 2016.

There may be events in the future that we are unable to predict accurately, or over which we have no control. You should completely read this Form 10-Q and the documents that we reference herein that have been filed or incorporated by reference as exhibits and with the understanding that our actual future results may be materially different from what we expect. Our business, financial condition, results of operations, and prospects may change. We may not update these forward-looking statements, even though our situation may change in the future, unless we have an obligation under the federal securities laws to update and disclose material developments related to previously disclosed information. We qualify all of the information presented in this Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

Aviragen is a registered trademark of Aviragen Therapeutics Inc., Relenza ^® is a registered trademark of GlaxoSmithKline plc, and Inavir ^® is a registered trademark of Daiichi Sankyo Company, Ltd.

References to “we,” “us,” and “our” refer to Aviragen Therapeutics, Inc. and its subsidiaries.

The following is a discussion and analysis of the major factors contributing to our results of operations for the three and six months ended December 31, 2016, and our financial condition at that date, and should be read in conjunction with the financial statements and the notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Company Overview

We are focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has four Phase 2 clinical programs: vapendavir, an oral treatment for rhinovirus (RV) upper respiratory infections in moderate-to-severe asthmatics; vapendavir, for the treatment of RV infections in hematopoietic stem cell transplant patients; BTA585, an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, a topical antiviral treatment for condyloma caused by human papillomavirus types 6 & 11. We also have preclinical RSV non-fusion inhibitor program that we believe complements our F-protein inhibitor BTA585.

Although several of our influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under license, collaboration or commercialization agreements with us, we have not independently developed or received regulatory approval for any product candidate, and we do not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that we may not derive any significant product revenues from any product candidates that we are developing now, or may develop in the future. We expect to incur losses for the foreseeable future as we intend to support the clinical and preclinical development of our product candidates.

We plan to continue to finance our operations with (i) our existing cash, cash equivalents, and investments (ii) proceeds from existing or potential future royalty-bearing licenses, collaborative research and development arrangements, (iii) future equity and/or forms of asset and debt financing or (iv) other financing arrangements. Our ability to continue to support our operations is dependent, in the near-term, upon our successful management of our cash resources, our continuing to receive royalty revenue under our existing licenses, our ability to enter into future collaboration, license or commercialization agreements, the successful development of our product candidates, our ability to execute future financings, if needed, and ultimately, upon the approval of our products for sale and achievement of positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to us, if at all, or that we will be able to enter into collaboration, license or commercialization agreements in the future, or that we will ever generate significant product revenue and become operationally profitable on a consistent basis.

Recent Clinical Highlights and Updates

Reported Data from the Phase 2a RSV Challenge Study of BTA585. On February 1, 2017, the Company announced top-line data from its double-blind, placebo-controlled Phase 2a study of BTA585 in adults challenged intranasally with respiratory syncytial virus (RSV). The data indicated there was not a significant reduction in the primary endpoint, which was viral load. The data suggested biological activity on several of the endpoints, however, the considerable variability in viral load among the cohorts and the small number of subjects that became infected with RSV likely impacted the ability to detect a significant difference between the groups. The safety profile of BTA585 was favorable and consistent across treatment groups. These safety results, together with the other clinical data and the recently completed non-clinical studies, will form the basis for the Company’s interaction with the FDA to discuss lifting the clinical hold on BTA585’s Investigational New Drug application.

Data Readout from Phase 2b SPIRITUS Trial. In February the Company expects to report results from the Phase 2b SPIRITUS trial of vapendavir for the treatment of rhinovirus (RV). The primary endpoint of this multi-center, randomized, double-blind, placebo-controlled dose-ranging study is the change from baseline to study day 14 measured by an asthma control questionnaire (ACQ)-6 total score. The secondary endpoints are focused on safety and tolerability, lung function assessments such as forced expiratory volume in one second (FEV1), incidence of asthma exacerbations, assessments of the severity and duration of cold symptoms measured by the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) and virological assessments.

Initiation of Phase 2 Trial of Vapendavir for Treatment of RV Infections in Hematopoietic Stem Cell Transplant (HSCT) Patients. In the third quarter of fiscal 2017, the Company expects to initiate a Phase 2 trial of vapendavir for the treatment of RV infections in HSCT patients. The primary endpoint of the trial will be time-weighted average change from baseline to end of treatment visit in RV viral load. Secondary endpoints will include mortality, rate of progression of RV in upper respiratory tract infection to lower respiratory tract infection, duration of RV shedding in HSCT subjects, and proportion with hospitalization and hospitalization time.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management’s Discussion and Analysis of Results of Operations discusses our financial results, which (except to the extent described in the Notes thereto) have been presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

We base our estimates and judgments on historical experience, current economic and industry conditions, and various other factors that we believe to be reasonable under the circumstances. This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no changes to our critical accounting policies that require significant judgment and estimates as discussed in detail in our 2016 annual 10-K filing:

	•		Use of estimates
	•		Revenue recognition
	•		Accrued expenses
	•		Share-based compensation

For a description of recent accounting policies and the impact on our financial statements, refer to Note 2 in the condensed consolidated financial statements.

Results of Operations for the Three months ended December 31, 2016 and December 31, 2015

Summary. For the three months ended December 31, 2016, we reported a net loss of $9.1 million, as compared to a net loss of $6.5 million in the same period of the prior fiscal year. Basic and diluted net loss per share was $0.24 for the three month period ended December 31, 2016, as compared to a basic and diluted net loss per share of $0.17 in the same period of 2015. The following commentary provides details underlying changes from last year in the major line items of our statement of operations:

Revenue. Revenue increased to $3.8 million for the three month period ended December 31, 2016 from $1.7 million in the same period in 2015 mainly due to the recognition in the 2016 period of non-cash royalty revenue related to the sale of certain royalty rights for Inavir® in Japan to HealthCare Royalty Partners III, L.P. in April 2016. The following table summarizes the key components of our revenue for the three months ended December 31, 2016 and 2015:

	Three Months Ended December 31,
	2016		2015
	(in millions)
Royalty revenue - Relenza^®	$	1.5	$	1.0
- Inavir^®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.8	$	1.7

Research and Development Expense. Research and development expense increased to $10.2 million for the three months ended December 31, 2016 from $6.3 million for the same period in 2015. The following table summarizes the components of our research and development expense for the three months ended December 31, 2016 and 2015.

	Three Months Ended December 31,
	(in millions)
	2016		2015

Direct preclinical, clinical and product development expenses	$	9.0	$	5.1
Salaries, benefits and share-based compensation expenses		1.1		1.0
Depreciation and facility related expenses		0.1		0.2
Total research and development expense	$	10.2	$	6.3

Direct preclinical, clinical and product development expense increased largely due to clinical and manufacturing costs associated with the Phase 2a challenge trial for BTA585, continuing costs for the Phase 2b SPIRITUS clinical trial for vapendavir, and clinical and chemistry expenses for BTA074 for the Phase 2 clinical trial that was initiated in February 2016.

General and Administrative Expense. General and administrative expense was $2.1 million for both the three months ended December 31, 2016 and the same period in 2015. The following table summarizes the components of our general and administrative expense for the three months ended December 31, 2016 and 2015.

	Three Months Ended December 31,
	(in millions)
	2016		2015

Salaries, benefits and share-based compensation expenses	$	1.1	$	1.1
Professional and legal fees expenses		0.4		0.4
Other expenses		0.6		0.6
Total general and administrative expense	$	2.1	$	2.1

Foreign Exchange Loss (Gain), net. The impact of foreign exchange changed from a gain of $0.2 million in December 31, 2015 to a loss of $0.1 million for three months ended December 31, 2016. The negative impact on foreign exchange on our statement of operations was due to fluctuations in foreign currency exchange rates versus the U.S. dollar, largely related to the Australian dollar. The vast majority of our cash holdings are held in the U.S. dollar. We re-measure all of our foreign assets and liabilities at the period-end exchange rate and the net effect of these translation adjustments is shown as a foreign currency loss or gain.

Results of Operations for the Six months ended December 31, 2016 and December 31, 2015

Summary. For the six months ended December 31, 2016, we reported a net loss of $19.1 million, as compared to a net loss of $13.2 million in the same period of the prior fiscal year. Basic and diluted net loss per share was $0.49 for the six month period ended December 31, 2016, as compared to a basic and diluted net loss per share of $0.34 in the same period of 2015. The following commentary provides details underlying changes from last year in the major line items of our statement of operations:

Revenue. Revenue increased to $3.9 million for the three month period ended December 31, 2016 from $3.4 million in the same period in 2015 mainly due to the recognition in the 2016 period of non-cash royalty revenue related to the sale of certain royalty rights for Inavir® in Japan to HealthCare Royalty Partners III, L.P. in April 2016. The following table summarizes the key components of our revenue for the six months ended December 31, 2016 and 2015.

	Six Months Ended December 31,
	2016		2015
	(in millions)
Royalty revenue - Relenza^®	$	1.6	$	2.7
- Inavir^®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.9	$	3.4

Research and Development Expense. Research and development expense increased to $17.8 million for the six months ended December 31, 2016 from $11.8 million for the same period in 2015. The following table summarizes the components of our research and development expense for the six months ended December 31, 2016 and 2015.

	Six Months Ended December 31,
	(in millions)
	2016		2015

Direct preclinical, clinical and product development expenses	$	15.4	$	9.4
Salaries, benefits and share-based compensation expenses		2.2		1.9
Depreciation and facility related expenses		0.2		0.5
Total research and development expense	$	17.8	$	11.8

General and Administrative Expense. General and administrative expense was $4.3 million for the six months ended December 31, 2016 compared to $4.4 million for the same period in 2015. The following table summarizes the components of our general and administrative expense for the six months ended December 31, 2016 and 2015.

	Six Months Ended December 31,
	(in millions)
	2016		2015

Salaries, benefits and share-based compensation expenses	$	2.0	$	2.5
Professional and legal fees expenses		1.1		0.6
Other expenses		1.2		1.3
Total general and administrative expense	$	4.3	$	4.4

Salaries, benefits and share-based compensation decreased primarily due to a reduction in administrative personnel. Professional and legal fees expenses increased due to timing of audit and tax fees incurred compared to the same period in the prior year.

Foreign Exchange Loss (Gain), net. The impact of foreign exchange changed from a loss of $0.5 million in December 31, 2015 to no impact for the six months ended December 31, 2016. The positive impact on foreign exchange on our statement of operations was due to fluctuations in foreign currency exchange rates versus the U.S. dollar, largely related to the British Pound and Australian Dollar. The vast majority of our cash holdings are held in the U.S. dollar. We re-measure all of our foreign assets and liabilities at the period-end exchange rate and the net effect of these translation adjustments is shown as a foreign currency loss or gain.

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended December 31, 2016, cash and cash equivalents decreased by $11.6 million. This decrease was primarily the result of our operating activities, offset in part by the maturity of short term investments.

Net cash used by operating activities was $19.7 million for the six months ended December 31, 2016, which reflected our net loss during the period of $19.1 million, net non-cash adjustments of $0.5 million, a net increase in operating assets of $1.5 million, offset by the net increase in operating liabilities of $1.4 million. Non-cash adjustments consist of $2.3 million in non-cash royalty income offset by $0.9 million in non-cash interest expense and $0.9 million in share-based compensation expense.

Our net loss resulted largely from our funding of research and development activities including conducting clinical and preclinical studies, manufacturing and formulation of our product candidates, as well as ongoing general and administrative expenses. The net change in operating assets reflects a $0.1 million increase in prepaid expenses and $1.4 million increase in accounts receivable, which is largely related to royalty income, offset by a $1.4 million increase in accounts payable and accrued expenses.

Net cash provided by investing activities during the six months ended December 31, 2016 consisted of the maturity of $16.6 million of investments, partially offset by the purchase of $8.4 million of investments.

At December 31, 2016, our cash, cash equivalents and investments totaled $49.2 million. Our cash and cash equivalents are currently held in the form of short-term deposits with large U.S. banks. Our short-term investments consist primarily of certificates of deposit and highly-rated corporate securities.

Our future funding requirements are difficult to determine and will depend on a number of factors, including:

●

the development timelines and plans for our product candidates, including any changes to those timelines, plans or our strategy;

●

the variability, timing and costs associated with conducting clinical trials for our product candidates, the rate of enrollment in such clinical trials, and the results of these clinical trials;

●

the variability, timing and costs associated with conducting preclinical studies, and the results of these studies;

●

the cost of scaling up, formulating and manufacturing preclinical and clinical trial materials to evaluate our product candidates;

●

whether we receive regulatory approval to advance or begin the clinical development of our product candidates in a timely manner, if at all;

●

the cost and time to obtain regulatory approvals required to advance the development of our product candidates;

●

the scope and size of our research and development efforts;

●

the variability of future royalty revenue we may receive from existing royalty-bearing license agreements;

●

the size and cost of the general and administrative function we need to manage our operations, including the infrastructure to support being a publicly-traded company; and

●

the cost of filing, prosecuting, and enforcing patent and other intellectual property claims.

Based on our current strategy and operating plan, and considering the potential costs associated with advancing the preclinical and clinical development of our product candidates, we believe that our existing cash, cash equivalents and investments of approximately $49.2 million, as well as our accounts receivable as of December 31, 2016, along with the anticipated proceeds from existing royalty-bearing licenses will enable us to operate for a period of at least 12 months.

We have an At-The-Market ("ATM") facility in place, which may allow us to quickly access the equity capital markets if we think it is prudent to do so and if market conditions allow. However, we currently do not have any commitments for future funding, nor do we anticipate that we will generate significant revenue, aside from revenue from existing royalty-bearing arrangements. Therefore, in order to meet our anticipated liquidity needs beyond 12 months to support the development of our product candidates, or possibly sooner in the event we enter into other transactions or revise our strategy or development plans, we may need to raise or secure additional capital. If we do, we would expect to do so primarily through the sale of additional common stock or other equity securities, as well as through proceeds from future licensing agreements, strategic collaborations, forms of asset or debt financing, or any other financing arrangement. Funds from these sources may not be available to us on acceptable terms, if at all, and our failure to raise such funds could have a material adverse impact on our future business strategy and plans, financial condition and results of operations. If adequate funds are not available to us on acceptable terms in the future, we may be required to delay, reduce the scope of, or eliminate one or more, if not all, of our research and development programs, or delay or curtail preclinical studies and clinical trials, or reduce our internal cost structure. If additional capital is not available to us on acceptable terms, we may need to obtain funds through license agreements, or collaborative or partner arrangements pursuant to which we will likely relinquish rights to certain product candidates that we might otherwise choose to develop or commercialize independently, or be forced to enter into such arrangements earlier than we would prefer, which would likely result in less favorable transaction terms. Additional equity financings may be dilutive to holders of our common stock, and debt financing, if available, may involve significant payment obligations and restrictive covenants that restrict how we operate our business.

Contractual and Commercial Commitments

There have been no material changes from the information included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) (ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

ITEM 3: Quantitative and Qualitative Disclosures about Market Risk

There has been no material change in our assessment of sensitivity to market risk since our presentation set forth in Item 7A “Quantitative and Qualitative Disclosures about Market Risk” in the our Annual Report on Form 10-K for the fiscal year ended June 30, 2016.

ITEM 4: Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Controls over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is involved in various legal proceedings that are incidental to the conduct of its business. The Company is not involved in any pending or threatened legal proceedings that it believes could reasonably be expected to have a material adverse effect on its financial condition or results of operations.

ITEM 1A. RISK FACTORS

Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and accompanying notes, and the additional information in the other reports we file with the Securities and Exchange Commission along with the risks described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you could lose part or all of your investment. We have described below those risks that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10‑K for the fiscal year ended June 30, 2016.

Royalty revenues from Relenza^® and Inavir^® are unpredictable and subject to the seasonal incidence and severity of influenza, which could adversely affect our results of operations and financial condition. Moreover, because we sold a portion of the royalty on Inavir^®, we expect our royalty cash flows from sales of Inavir^®to be substantially lower than historical levels.

We currently earn royalty revenue from the net sales of Relenza^® and Inavir^®, which are marketed by our licensees. Although the royalty rates paid to us by our licensees are fixed at a proportion of our licensees’ net sales of these products, our periodic and annual revenues from these royalties have historically been variable and subject to fluctuation based on the seasonal incidence and severity of influenza. In addition, returns of products to our licensees that were sold in prior years are taken into account in the calculation of net sales for purposes of determining the royalty revenue we receive and the amount of such returns are generally unpredictable. We cannot predict with any certainty what our royalty revenues are likely to be in any given year. Because we sold a portion of the royalty on Inavir^®, we expect our Inavir^® royalty cash flows to be substantially lower than historical levels. Further, most of our Relenza^® patents have expired and the only substantial remaining intellectual property related to the Relenza^® patent portfolio, which is solely owned by us and exclusively licensed to GSK, is scheduled to expire in July 2019 in Japan.

If we are unable to adequately protect or expand our intellectual property related to our products, or current or future product candidates, our business prospects could be materially harmed.

Our business success depends in part on our ability to:

●

obtain, maintain and protect our intellectual property rights;

●

protect our trade secrets; and

●

prevent others from infringing on our proprietary rights or patents.

We can protect our proprietary intellectual property rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of pharmaceutical and biopharmaceutical companies involves complex legal and factual questions, and, therefore, we cannot predict with certainty whether we will be able to ultimately enforce our patents or proprietary rights, or avoid infringing on the patents or proprietary rights of others. Any issued patents that we own or otherwise have rights to may be challenged, invalidated or circumvented, and may not provide us with the protection against competitors that we anticipate.

The degree of future protection for our proprietary intellectual property rights is uncertain because issued patents and other legal means of establishing proprietary rights afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. Our future patent position will be influenced by the following factors:

●

we, or our licensors, may not have been the first to discover the inventions covered by each of our or our licensors’ pending patent applications and issued patents, and we may have to engage in expensive and protracted interference proceedings to determine priority of invention;

●

our, or our licensors’, pending patent applications may be denied and may not result in issued patents;

●

our, or our licensors’, issued patents may not provide a basis for commercially viable products, may not provide us with any competitive advantages, or may be challenged by third parties; and

●

third parties may develop intellectual property that circumvents our or our licensors’ patent claims or design competitive intellectual property and ultimately product candidates that fall outside the scope of our or our licensors’ patents.

Due to the extensive time required for the development, testing and regulatory review and approval of a product candidate, it is possible that before a product candidate of ours may be approved for sale and commercialized, our relevant patent rights may expire, or such patent rights may remain in force for only a short period following marketing approval. We currently rely on certain patents to provide us and our licensees with exclusive rights for certain of our products. When all patents underlying a license expire, our revenue from that license may cease, and there can be no assurance that we will be able to replace it with revenue from new or existing licenses.

Zanamivir, a neuraminidase inhibitor approved for the treatment and prevention of influenza A and B, is marketed worldwide as Relenza^® by GSK. Most of our Relenza^® patents have expired and the only substantial remaining intellectual property related to the Relenza^® patent portfolio, which is solely owned by us and exclusively licensed to GSK, is scheduled to expire in July 2019 in Japan. On October 18, 2016, the United States Court of Appeals for the Federal Circuit affirmed the rejection of all pending claims of U.S. Patent Application No. 08/737,141. Accordingly, no future United States royalties beyond those previously committed will be owed by GSK.

LANI, a long acting NI for the treatment and prevention of influenza A and B, is currently marketed as Inavir^® in Japan by Daiichi-Sankyo. The patent relating to the structure of LANI expires in 2017 in the U.S., the EU and Japan. The patent relating to hydrates and the crystalline form of LANI actually used in the product expires in 2021 (not including extensions) in the U.S. and EU and in 2024 in Japan. In February 2015, a patent containing claims relevant to the manufacture of Inavir^® was issued in Japan and expires in December 2029. The dry-powder inhaler device patent portfolio, which includes TwinCaps^®, is owned by Hovione International Limited (“Hovione”) and is exclusively licensed to us and Daiichi Sankyo worldwide for the prevention and treatment of influenza and other influenza-like viral infections. These patents will expire in 2029 in the U.S., and in 2027 in the EU and Japan.

Vapendavir is an oral direct acting antiviral we are developing to treat HRV infections. We exclusively own the vapendavir patent portfolio, and issued claims under this portfolio will begin to expire in some countries in December 2021, not including extensions. Claims filed in recent patent applications related to a free-base form of vapendavir, if allowed, would extend coverage until 2034, without extensions, however we cannot make any assurance that these claims will be allowed.

BTA074 is a direct-acting antiviral we are developing as a topical treatment for genital warts caused by HPV 6 and 11. The patent containing composition of matter claims expires in the U.S. in 2029 without extensions. Pending U.S. patent applications related to pharmaceutical compositions and methods of synthesis of BTA074 if allowed, would extend coverage until 2033, without extensions, however we cannot make any assurance that these claims will be allowed.

We also own a patent portfolio focused on developing oral antivirals for RSV. Issued patent claims covering the BTA585 composition of matter will begin to expire in 2031 without extensions.

Patent rights may not provide us with adequate proprietary protection or competitive advantages against competitors with or developing similar technologies or approaches to ours. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the U.S., and certain countries may lack adequate rules and procedures for defending our intellectual property rights. For example, we may not be able to prevent a third party from infringing our patents in a country that does not recognize or enforce patent rights, or that imposes compulsory licenses on or restricts the prices of drugs. Changes in either patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. We may need to in-license certain technologies to successfully develop and commercialize our product candidates. We may not develop or obtain rights to products or processes that are patentable. Even if we or our licensors do obtain patents, such patents may not adequately protect the products or technologies licensed, or may otherwise be limited in scope. In addition, we may not have total control over the patent prosecution of subject matter that we license from others. Accordingly, we may be unable to exercise the same degree of control over this intellectual property as we would over our own. Others may challenge, seek to invalidate, infringe or circumvent any pending or issued patents we own or license, and rights we receive under those issued patents may not provide competitive advantages to us. We cannot assure you of the degree of protection that will be afforded by any of our issued or pending patents, or those licensed by us.

We cannot be sure that any patents will be issued from the patent applications we own or have licensed or, should any patents issue, that we will be provided with adequate protection against potentially competitive products. Furthermore, we cannot be sure that patents issued or licensed to us will be of any commercial value, or that private parties or competitors will not successfully challenge these patents or circumvent our patent position in the U.S. or abroad. In the absence of adequate patent protection, our business may be adversely affected by competitors who develop comparable technology or products.

Our certificate of incorporation, our bylaws, and the laws of Delaware contain provisions that could discourage, delay or prevent a change in our control or in our management.

Certain provisions of our restated certificate of incorporation, our bylaws and the laws of Delaware, the state in which we are incorporated, may discourage, delay or prevent a change in control of us or a change in our directors or management that stockholders may consider favorable. These provisions:

●

allow the authorized number of directors to be changed only by resolution of our Board of Directors;

●

removal of Directors from office at any time, but only by the affirmative vote of the holders of at least seventy-five (75%) of the voting power of all of the then-outstanding shares of capital stock of the corporation entitled to vote generally in the election of Directors;

●

authorize our Board of Directors to issue without stockholder approval, up to 5,000,000 shares of preferred stock, the rights of which will be determined at the discretion of the Board of Directors that, if issued, could operate as a “poison pill” to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our Board of Directors;

●

establish advance notice requirements for stockholder nominations to our Board of Directors or for stockholder proposals that can be acted on at stockholder meetings;

●

limit who may call stockholder meetings; and

●

contain a fair price provision.

In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights of our common stock, from merging or combining with us for a prescribed period of time. These provisions could discourage proxy contests and make it more difficult for you and other stockholders to remove and elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits to this report are listed in the Exhibit Index, which is incorporated into this Item 6 by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Aviragen Therapeutics, Inc.

Date: February 6, 2017	By:	/s/ Joseph M. Patti
		Joseph M. Patti Chief Executive Officer (Principal Executive Officer)

	By:	/s/ Mark Colonnese
		Mark P. Colonnese Executive Vice President and Chief Financial Officer (Principal Financial Officer)

EXHIBIT INDEX

		Filed	Incorporation by Reference
Exhibit Number	Exhibit Title	with this Form 10-Q	Form	File No.	Date Filed
31.1*	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended	X

31.2*	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended	X

32.1*	Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350	X

101	The following financial information from the Aviragen Therapeutics, Inc. Quarterly Report on Form 10-Q for the period ended December 31, 2016 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations for the Three months, (iii) the Condensed Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements	X

* This certification is being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of Aviragen Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-31.1 2 ex31-1.htm EXHIBIT 31.1 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Joseph M. Patti, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Aviragen Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 6, 2017	By:	/s/ Joseph M. Patti
		Joseph M. Patti
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm EXHIBIT 31.2 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Mark P. Colonnese, certify that:

6.	I have reviewed this quarterly report on Form 10-Q of Aviragen Therapeutics, Inc.;

7.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

8.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

10.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 6, 2017	By:	/s/ Mark Colonnese
		Mark Colonnese
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 ex32-1.htm EXHIBIT 32.1 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Aviragen Therapeutics, Inc. (“the Company”) for the quarterly period ended December 31, 2016 (the “Report”), I, Joseph M. Patti, Chief Executive Officer of the Company, and Mark P. Colonnese, Chief Financial Officer of the Company each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

●

To my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

●

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 6, 2017	By:	/s/ Joseph M. Patti
		Joseph M. Patti
		Chief Executive Officer
		(Principal Executive Officer)


	By:	/s/ Mark Colonnese
		Mark P. Colonnese
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 5 avir-20161231.xml XBRL INSTANCE DOCUMENT 4600000 2200000 P1Y 10000 200000 900000 500000 900000 2300000 2300000 20000000 0.07 0.1 0.04 false --06-30 Q2 2017 2016-12-31 10-Q 0000072444 38649237 Yes Accelerated Filer Aviragen Therapeutics, Inc. No No avir

3400000

3900000

2200000

200000

4200000

700000

5600000

3600000

500000

100000

19000000

158500000

157600000

900000

500000

600000

900000

1200000

5645543

4631556

5645543

4619210

56500000

72700000

56200000

72400000

21800000

7700000

14100000

20800000

11500000

9300000

100000

7700000

9400000

3000000

1700000

21800000

1500000

2000000

7000000

2900000

7300000

20700000

7700000

9400000

3000000

1700000

21800000

1500000

2000000

7000000

3000000

7300000

20800000

10700000

7700000

3000000

11100000

1500000

19300000

10000000

9300000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recent Accounting Standards</div></div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the Financial Accounting Standards Board ("FASB") issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods b<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">eginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Accordingly, the Company will adopt this guidance on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> Companies <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the FASB issued authoritative accounting guidance related to management<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for annual reporting ending after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> and for annual periods and interim periods thereafter, with early application permitted. Accordingly, the standard is effective for the Company on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Accordingly, the standard is effective for the Company on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> The Company is currently evaluating the impact that the standard will have on the consolidated financial statements.</div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements.</div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued guidance on stock compensation. This guidance simplifies the accounting for the taxes related to stock based compensation, including adjustments to how excess tax benefits and a company's payments for tax withholdings should<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> be classified. The guidance is effective for public companies for annual periods, and interim periods within those annual periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> and early adoption is permitted. The Company is currently evaluating the impact that the guidance will have on the consolidated financial statements.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">new guidance on how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for the Company beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the FASB amended and clarified guidance related to b<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">usiness combinations and the definition of a business. The guidance is effective for annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> including interim periods within those periods. Accordingly, the amendments are effective for the Company beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.</div></div></div></div>

38100000

49700000

44700000

39000000

-11600000

-5700000

0.10

200000000

38640487

3900000

18100000

18800000

20000000

1200000

1300000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5)</div>    Liabilities Related to Sale of Future Royalties </div></div></div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company sold certain royalty rights related to the approved product Inavir<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">®</div>, sold by Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in the Japanese market, for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20</div> million to HealthCare Royalty Partners III, L.P. (“HCRP”). Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the arrangement, this transaction was accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the amount receivable from Daiichi Sankyo related to the HCRP transaction was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.2</div> million, respectively, which has been included in “Accounts Receivable” in the accompanying condensed consolidated balance sheets. </div></div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In order to record the amortization of the liability, the Company is requir<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">ed to estimate the total amount of future royalty payments to be received under the License Agreement with Daiichi Sankyo and the payments that will be passed through to HCRP over the life of the agreement. The sum of the pass through amounts less the net proceeds received will be recorded as non-cash interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The Company will periodically assess the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company will adjust the amortization of the liability and interest rate. As a result of this accounting, even though the Company does not retain HCRP’s share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability and related interest is fully amortized</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div><div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The following table shows the activity within the liability account during the <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div> </div></div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-right: 20%; margin-left: 36pt;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">in millions</div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 81%; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Total Liability related to sale of future royalties, June 30, 201<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">6</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 12pt;"> <div style=" margin: 0pt; text-align: left; text-indent: 9pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">Non-cash<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> royalty revenue paid to HCRP </div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 12pt;"> <div style=" margin: 0pt; text-align: left; text-indent: 9pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">Non-cash interest expense recognized</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.9</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Total Liability related to sale of future royalties, <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">December 31, 2016</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div></div>

17600000

16800000

-0.24

-0.17

-0.49

-0.34

-0.24

-0.17

-0.49

-0.34

-0.24

-0.17

-0.49

-0.34

500000

600000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" nowrap="nowrap" style="padding: 0px; width: 0%; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Quoted Prices in</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Significant</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Active Markets </div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Other</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Significant</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in millions)</div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">for </div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Identical</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Assets</div></div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Observable </div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Inputs</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unobservable</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Inputs</div></div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">, 201</div><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments available-for-sale</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" nowrap="nowrap" style="padding: 0px; width: 0%; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Quoted Prices in </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Significant</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Active Markets</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Other </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Significant</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">for </div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Identical</div></div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Observable</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Unobservable</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;">(in millions)</td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Assets</div></div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Inputs</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Inputs</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">June 30, 201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments available-for-sale</div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt;">19.3</div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.0</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.5</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3)</div>     Fair Value Measurements</div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">A fair value hierarchy has been established <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">that requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of inputs that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be used to measure fair value: </div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr> <td style="width: 8%; vertical-align: top;"> </td> <td style="width: 9%; vertical-align: top;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> </div></div> </td> <td style="width: 83%; vertical-align: top;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Quoted prices in active markets for identical assets or liabilities.</div> </td> </tr> <tr> <td style="width: 8%; vertical-align: top;"> </td> <td style="width: 9%; vertical-align: top;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> </div></div> </td> <td style="width: 83%; vertical-align: top;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Observable inputs other than Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div> </td> </tr> <tr> <td style="width: 8%; vertical-align: top;"> </td> <td style="width: 9%; vertical-align: top;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> </div></div> </td> <td style="width: 83%; vertical-align: top;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div> </td> </tr> </table> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">T<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">he Company’s short-term investments have been classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" nowrap="nowrap" style="padding: 0px; width: 0%; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Quoted Prices in</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Significant</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Active Markets </div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Other</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Significant</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in millions)</div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">for </div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Identical</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Assets</div></div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Observable </div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Inputs</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unobservable</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Inputs</div></div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">, 201</div><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments available-for-sale</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" nowrap="nowrap" style="padding: 0px; width: 0%; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Quoted Prices in </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Significant</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Active Markets</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Other </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Significant</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">for </div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Identical</div></div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Observable</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Unobservable</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt; vertical-align: bottom;">(in millions)</td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Assets</div></div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;">Inputs</div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Inputs</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">June 30, 201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments available-for-sale</div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt;">19.3</div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.0</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.5</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Cash equivalents consist primarily of money market funds. Short-term investments consist of certificates of deposit, corporate securities, U.S. Treasury securities and U.S. agency securities, classified as available-for-sale and have maturities less than<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">365</div> days from the date of acquisition. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The following table shows the unrealized gains and losses and fair values for those investments as of <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> aggregated by major security type: </div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in millions)</div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">, 201</div><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Cost</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gains</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Losses)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Fair Value</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate notes</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt;"></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in millions)</div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">June 30, 201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Cost</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gains</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Losses)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Fair Value</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Debt securities of U.S. government agencies</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Treasury securities</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate notes</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had no investments in an unrealized gain (loss) position.<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">  As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company had investments in an unrealized gain position. The Company has determined that the unrealized gains on these investments are temporary in nature and expects the security to mature at its stated maturity principal. All available-for-sale securities held at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> will mature within a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year period. The fair value of cash, accounts receivable, accounts payable and accrued liabilities approximate their carrying value because of the short-term nature of these financial instruments respectively, at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The fair value of the Company’s short-term note payable, which is measured using Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs, approximates book value, at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div></div>

-100000

200000

-500000

2100000

4300000

4400000

-9000000

-6500000

-19000000

-13200000

100000

1400000

-2800000

1400000

-7500000

100000

900000

100000

28500000

26500000

56500000

72700000

10500000

9200000

200000

300000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1)</div>     </div> <div style="display: inline; font-weight: bold;">Company Overview</div></div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> clinical programs: vapendavir, an oral treatment for rhinovirus (RV) upper respiratory infections in moderate-to-severe asthmatics; vapendavir, for the treatment of RV infections in hematopoietic stem cell transplant patients; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BTA585,</div> an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus ("RSV") infections; and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BTA074,</div> a topical antiviral treatment for condyloma caused by human papillomavirus types <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> & <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div> The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia.</div></div> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Although several of the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not successfully derive any significant product revenues from any product candidates that it is developing now, or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates. </div></div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The Company plans to continue to finance its operations with (i) existing cash, cash equivalents and investments, (ii) proceeds from existing or potential future royalty-bearing licenses or collaborative research and development arrangements, (iii) future equity and/or asset or debt financings, or (iv)other financing arrangements. The Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources, continuing to receive royalty revenue under existing licenses, entering into future collaboration, license or commercialization agreements, the successful development of its product candidates, executing future financings and ultimately, upon the approval of its products for sale and achieving positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to the Company, if at all, that the Company will be able to enter into collaboration, license or commercialization agreements in the future, or that the Company will ever generate significant product revenue and become operationally profitable on a consistent basis.</div></div></div>

-100000

8200000

2600000

-19700000

-8200000

-9100000

-6500000

-19100000

-13200000

-19100000

-400000

-800000

100000

300000

400000

12400000

8200000

22100000

16700000

-8600000

-6500000

-18200000

-13300000

700000

200000

8400000

6400000

0.10

5000000

2800000

2700000

16600000

9000000

300000

100000

10200000

6300000

17800000

11800000

-153400000

-134300000

3800000

1700000

3900000

3400000

1500000

1700000

1600000

3400000

1500000

1000000

700000

1600000

2700000

700000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0pt 0pt; text-indent: 0px; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 3.6pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">,</div></div></div></div> <div style=" margin: 0pt 3.6pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 2.6pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 3.6pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style="display: inline; font-weight: bold;">30,</div></div></div></div> <div style=" margin: 0pt 3.6pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">fees</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Salary and <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">benefits </div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">development expenses</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">expenses</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses and other liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.6</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.6</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 5.8pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div><br /> <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 1.8pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 1.8pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">5</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Net <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">loss (in millions)</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6.5</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Weighted-average shares outstanding</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,640,487</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,636,946</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Dilutive effect of restricted stock and stock options</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Shares used to compute diluted earnings per share</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,640,487</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,636,946</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 12pt;"> <div style=" margin: 0pt 0.8pt 0pt 12pt; text-align: left; text-indent: -12pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">Basic <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">net loss per share</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.24</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.17</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 12pt;"> <div style=" margin: 0pt 0.8pt 0pt 12pt; text-align: left; text-indent: -12pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">Diluted net <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">loss per share</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.24</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.17</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Number of anti-dilutive share-based awards excluded from computation</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,645,543</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,631,556</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 5.8pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> Months Ended</div><br />  <div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 1.8pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 1.8pt 0pt 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">5</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Net <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">loss (in millions)</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13.2</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Weighted-average shares outstanding</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,640,487</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,630,587</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Dilutive effect of restricted stock and stock options</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Shares used to compute diluted earnings per share</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,640,487</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,630,587</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 12pt;"> <div style=" margin: 0pt 0.8pt 0pt 12pt; text-align: left; text-indent: -12pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">Basic net <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">income (loss) per share</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.49</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.34</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 12pt;"> <div style=" margin: 0pt 0.8pt 0pt 12pt; text-align: left; text-indent: -12pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">Diluted net loss<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> per share</div></div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.49</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.34</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt 0.8pt 0pt 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Number of anti-dilutive share-based awards excluded from computation</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,645,543</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,619,210</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> </td> </tr> </table></div>

900000

1200000

4794137

11100000

19300000

3900000

157600000

-134300000

19000000

46200000

3900000

158500000

-153400000

19000000

28000000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in millions)</div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">December 31</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">, 201</div><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Cost</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gains</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Losses)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Fair Value</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate notes</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <tr style="vertical-align: bottom;"> <td style="width: 52%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(in millions)</div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Unrealized</div></div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">June 30, 201</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">6</div> </div></div> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Cost</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gains</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Losses)</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At Fair Value</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div></div></div> </td> <td style="padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Debt securities of U.S. government agencies</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Treasury securities</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate notes</div> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.3</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style=" font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.7</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.8</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

38640487

38636946

38640487

38630587

38640487

38636946

38640487

38630587

38640487

38636946

38640487

38630587

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000072444 2015-07-01 2015-12-31 0000072444 avir:InavirMember 2015-07-01 2015-12-31 0000072444 avir:RelenzaMember 2015-07-01 2015-12-31 0000072444 2015-10-01 2015-12-31 0000072444 avir:InavirMember 2015-10-01 2015-12-31 0000072444 avir:RelenzaMember 2015-10-01 2015-12-31 0000072444 avir:HealthcareRoyaltyIIILPMember us-gaap:RoyaltyArrangementMember 2016-04-01 2016-04-30 0000072444 avir:HealthcareRoyaltyIIILPMember 2016-04-22 2016-04-22 0000072444 2016-07-01 2016-12-31 0000072444 avir:DaiichiSankyoMember avir:JapanMember 2016-07-01 2016-12-31 0000072444 avir:GSKMember avir:AustraliaNewZealandSouthAfricaAndIndonesiaMember 2016-07-01 2016-12-31 0000072444 avir:GSKMember avir:UnitedStatesEuropeJapanAndOtherCountriesMember 2016-07-01 2016-12-31 0000072444 avir:GeorgiaStateUniversityResearchFoundationGSURFMember 2016-07-01 2016-12-31 0000072444 avir:HealthcareRoyaltyIIILPMember us-gaap:RoyaltyArrangementMember 2016-07-01 2016-12-31 0000072444 avir:InavirMember 2016-07-01 2016-12-31 0000072444 avir:RelenzaMember 2016-07-01 2016-12-31 0000072444 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2016-12-31 0000072444 us-gaap:RetainedEarningsMember 2016-07-01 2016-12-31 0000072444 2016-10-01 2016-12-31 0000072444 avir:InavirMember 2016-10-01 2016-12-31 0000072444 avir:RelenzaMember 2016-10-01 2016-12-31 0000072444 2015-06-30 0000072444 2015-12-31 0000072444 2016-06-30 0000072444 avir:DaiichiSankyoMember 2016-06-30 0000072444 avir:HealthcareRoyaltyIIILPMember us-gaap:RoyaltyArrangementMember 2016-06-30 0000072444 us-gaap:FairValueInputsLevel1Member 2016-06-30 0000072444 us-gaap:FairValueInputsLevel1Member us-gaap:CashEquivalentsMember 2016-06-30 0000072444 us-gaap:FairValueInputsLevel1Member us-gaap:ShortTermInvestmentsMember 2016-06-30 0000072444 us-gaap:FairValueInputsLevel2Member 2016-06-30 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2016-06-30 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2016-06-30 0000072444 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:CashEquivalentsMember 2016-06-30 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:ShortTermInvestmentsMember 2016-06-30 0000072444 us-gaap:CashEquivalentsMember 2016-06-30 0000072444 us-gaap:CertificatesOfDepositMember 2016-06-30 0000072444 us-gaap:CorporateNoteSecuritiesMember 2016-06-30 0000072444 us-gaap:MoneyMarketFundsMember 2016-06-30 0000072444 us-gaap:ShortTermInvestmentsMember 2016-06-30 0000072444 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2016-06-30 0000072444 us-gaap:USTreasurySecuritiesMember 2016-06-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0000072444 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000072444 us-gaap:CommonStockMember 2016-06-30 0000072444 us-gaap:RetainedEarningsMember 2016-06-30 0000072444 avir:The2016EquityPlanMember 2016-11-10 0000072444 2016-12-31 0000072444 avir:DaiichiSankyoMember 2016-12-31 0000072444 avir:HealthcareRoyaltyIIILPMember us-gaap:RoyaltyArrangementMember 2016-12-31 0000072444 us-gaap:FairValueInputsLevel1Member 2016-12-31 0000072444 us-gaap:FairValueInputsLevel1Member us-gaap:CashEquivalentsMember 2016-12-31 0000072444 us-gaap:FairValueInputsLevel1Member us-gaap:ShortTermInvestmentsMember 2016-12-31 0000072444 us-gaap:FairValueInputsLevel2Member 2016-12-31 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember 2016-12-31 0000072444 us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2016-12-31 0000072444 us-gaap:FairValueInputsLevel3Member 2016-12-31 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:CashEquivalentsMember 2016-12-31 0000072444 us-gaap:FairValueInputsLevel3Member us-gaap:ShortTermInvestmentsMember 2016-12-31 0000072444 us-gaap:CashEquivalentsMember 2016-12-31 0000072444 us-gaap:CertificatesOfDepositMember 2016-12-31 0000072444 us-gaap:CommercialPaperMember 2016-12-31 0000072444 us-gaap:CorporateNoteSecuritiesMember 2016-12-31 0000072444 us-gaap:MoneyMarketFundsMember 2016-12-31 0000072444 us-gaap:ShortTermInvestmentsMember 2016-12-31 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000072444 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000072444 us-gaap:CommonStockMember 2016-12-31 0000072444 us-gaap:RetainedEarningsMember 2016-12-31 0000072444 2017-02-06

EX-101.SCH 6 avir-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Company Overview link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Accrued and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 3 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 4 - Accrued and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Fair Value Measurements - Summary of Investments (Details) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 3 - Fair Value Measurements - Unrealized Gain (Loss) on Investments (Details) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements - Components of Revenues From Royalties, Collaborative and Contractual Agreements (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 8 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 avir-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 avir-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 avir-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual statementsignificantaccountingpoliciespolicies statementnote3fairvaluemeasurementstables statementnote4accruedandothercurrentliabilitiestables statementnote5liabilitiesrelatedtosaleoffutureroyaltiestables Total statementnote6netlosspersharetables statementnote7licensesroyaltycollaborativeandcontractualarrangementstables statementnote3fairvaluemeasurementssummaryofinvestmentsdetails statementnote3fairvaluemeasurementsunrealizedgainlossoninvestmentsdetails statementnote4accruedandothercurrentliabilitiessummaryofaccruedandothercurrentliabilitiesdetails statementnote5liabilitiesrelatedtosaleoffutureroyaltiesdeferredrevenueactivitydetails statementnote6netlosspersharecomputationofhistoricalbasicanddilutednetlosspersharedetails statementnote7licensesroyaltycollaborativeandcontractualarrangementscomponentsofrevenuesfromroyaltiescollaborativeandcontractualagreementsdetails Notes To Financial Statements Notes To Financial Statements [Abstract] Accounts payable and accrued expenses The 2016 Equity Plan [Member] Represents information pertaining to the 2016 Equity Incentive Plan ("2016 Equity Plan"), which replaced and superseded the amended 2007 Omnibus Equity and Incentive Plan ("Prior Plan"). Available for Sale Securities - Current Fair Value Basis of Accounting, Policy [Policy Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Accounting Policies [Abstract] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before tax Operating expense: Total revenue Total revenue Preferred stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) Balances (in shares) Balances (in shares) Interest income Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Nature of Operations [Text Block] us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Prepaid and other current assets us-gaap_RepaymentsOfNotesPayable Payment on note payable Share-based compensation us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Products and Services [Domain] Products and Services [Axis] us-gaap_DeferredRevenueAdditions Deferred Revenue, Additions Plan Name [Axis] Plan Name [Domain] Basic and diluted weighted-average shares outstanding (in shares) Number of anti-dilutive share-based awards excluded from computation (in shares) us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Shares used to compute diluted earnings per share (in shares) Basic and diluted net loss per share (in dollars per share) Geographical [Axis] Geographical [Domain] us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivables Royalty revenue Diluted net loss per share (in dollars per share) Diluted net loss per share (in dollars per share) us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Royalty Arrangement [Member] us-gaap_AccountsReceivableNet Accounts Receivable, Net us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Weighted-average shares outstanding (in shares) Scenario, Unspecified [Domain] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Scenario [Axis] Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Basic net loss per share (in dollars per share) Basic net income (loss) per share (in dollars per share) Deferred Revenue Disclosure [Text Block] Georgia State University Research Foundation (GSURF) [Member] Represents the Georgia State University Research Foundation (GSURF). avir_CollaborativeArrangementAnnualMinimumPayment Collaborative Arrangement, Annual Minimum Payment Represents the annual minimum cash outflow associated with a collaborative arrangement. Fair Value Disclosures [Text Block] Schedule of Accrued Liabilities [Table Text Block] Statement [Table] Short-term Investments [Member] Other long-term liabilities, net of current portion Income Statement [Abstract] HealthCare Royalty Partners III, L.P. [Member] Represents the legal entity, HealthCare Royalty III, L.P. avir_ProceedsFromSaleOfRoyaltyRightsGross Proceeds From Sale of Royalty Rights, Gross The cash inflow from sale of royalty rights, before any expenses incurred to carry out the sale. Cash flows from financing activities: us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Accumulated deficit Accumulated other comprehensive income Stockholders’ equity: Unrealized Gain (Loss) on Investments [Table Text Block] Liability related to sale of future royalties, net of current portion avir_RoyaltyPaymentPercentage Royalty Payment Percentage Represents royalty payment percentage. Investment Type [Axis] GSK [Member] This item represents transactions between the Company and GSK. Investments [Domain] Research and development expenses Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development materials and services costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been paid. Australia, New Zealand, South Africa, and Indonesia [Member] This item represents activity in Australia, NewZealand, South Africa, and Indonesia. Japan [Member] This item represents activity in Japan. Daiichi Sankyo [Member] This item represents transactions between the Company and Daiichi Sankyo. Relenza [Member] This item represents the Relenza product line. United States, Europe, Japan, And Other Countries [Member] The geographical location of the particular royalty payment percentages. Inavir [Member] This item represents the Inavir product line. Fair Value, Assets Measured on Recurring Basis [Table Text Block] Long-term note payable, net of current portion Change in operating assets and liabilities: Income tax expense Non-current liabilities: us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign exchange (gain) loss, net Class of Stock [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_ShareBasedCompensation Share-based compensation Liability related to sale of future royalties, current portion Counterparty Name [Domain] Common stock, $0.10 par value: 200,000,000 shares authorized; 38,640,487 shares issued and outstanding at December 31, 2016 and June 30, 2016 us-gaap_TableTextBlock Notes Tables Maturity of short-term investments us-gaap_PaymentsToAcquireInvestments Purchases of short and long-term investments Counterparty Name [Axis] Short-term note payable Common stock, shares issued (in shares) Certificates of Deposit [Member] Common stock, shares authorized (in shares) Commercial Paper [Member] Amendment Flag US Government Agencies Debt Securities [Member] Common stock, par value (in dollars per share) US Treasury Securities [Member] Collaborative Arrangement Disclosure [Text Block] Revenue: us-gaap_AssetsCurrent Total current assets Non-current assets: us-gaap_NonoperatingIncomeExpense Total other (expense) income Preferred stock, $0.10 par value: 5,000,000 shares authorized, no shares issued and outstanding General and administrative Current Fiscal Year End Date Preferred stock, shares issued (in shares) Adjustments to reconcile net loss to net cash used in operating activities: Statement of Financial Position [Abstract] Preferred stock, shares authorized (in shares) Document Fiscal Period Focus Salary and benefits Document Fiscal Year Focus Accounts payable Preferred stock, par value (in dollars per share) Accrued expenses Total accrued expenses and other liabilities Document Period End Date Non-cash royalty revenue related to the sale of future royalties Non-cash royalty revenue related to sale of future royalties Non-cash revenue earned for sales of future royalties from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Examples of property from which royalties may be derived include patents and oil and mineral rights. Document Type Non-cash interest expense related to sale of future royalties Non-cash interest expense on liability related to sale of future royalties Amount of non-cash accounted for as interest expense on liability in relation to the sale of future royalties. us-gaap_OperatingIncomeLoss Loss from operations Statement of Cash Flows [Abstract] Other (expense) income: Statement of Stockholders' Equity [Abstract] Document Information [Line Items] Document Information [Table] Entity Filer Category us-gaap_OtherAccruedLiabilitiesCurrent Other accrued expenses Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer us-gaap_AccruedProfessionalFeesCurrent Professional fees Basis of Presentation and Significant Accounting Policies [Text Block] avir_AvailableForSaleSecuritiesMaturityPeriod Available-for-Sale Securities, Maturity Period Represents the period over which available-for-sale securities mature. Entity Central Index Key Entity Registrant Name Entity [Domain] Current liabilities: Legal Entity [Axis] us-gaap_Assets Total assets Additional paid-in capital Entity Common Stock, Shares Outstanding (in shares) Cash flows from operating activities: Statement [Line Items] Trading Symbol AOCI Attributable to Parent [Member] Accounts receivable, net of allowance us-gaap_Liabilities Total liabilities Commitments and contingencies Short-term investments Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Money Market Funds [Member] Fair Value, Hierarchy [Axis] Current assets: Cash Equivalents [Member] us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Decrease in cash and cash equivalents Net loss Net loss us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net cash used in financing activities us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net cash provided by investing activities avir_DeferredRevenueNonCashRoyaltyRevenuePaid Non-cash royalty revenue paid to HCRP Amount of non-cash royalty revenue paid on liability in relation to the sale of future royalties. Property and equipment, net Non-cash interest expense recognized Amount of non-cash interest expense recognized in relation to the sale of future royalties. Unrealized Gains Corporate Note Securities [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Unrealized (Losses) EX-101.PRE 10 avir-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2016	Feb. 06, 2017
Document Information [Line Items]
Entity Registrant Name	Aviragen Therapeutics, Inc.
Entity Central Index Key	0000072444
Trading Symbol	avir
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		38,649,237
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 38.1	$ 49.7
Short-term investments	11.1	19.3
Accounts receivable, net of allowance	4.2	0.7
Prepaid and other current assets	2.8	2.7
Total current assets	56.2	72.4
Non-current assets:
Property and equipment, net	0.3	0.3
Total assets	56.5	72.7
Current liabilities:
Accounts payable	3.4	3.9
Accrued expenses	5.6	3.6
Short-term note payable	0.3	0.4
Liability related to sale of future royalties, current portion	1.2	1.3
Total current liabilities	10.5	9.2
Non-current liabilities:
Long-term note payable, net of current portion	0.2	0.3
Liability related to sale of future royalties, net of current portion	17.6	16.8
Other long-term liabilities, net of current portion	0.2	0.2
Total liabilities	28.5	26.5
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.10 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.10 par value: 200,000,000 shares authorized; 38,640,487 shares issued and outstanding at December 31, 2016 and June 30, 2016	3.9	3.9
Additional paid-in capital	158.5	157.6
Accumulated other comprehensive income	19.0	19.0
Accumulated deficit	(153.4)	(134.3)
Total stockholders’ equity	28.0	46.2
Total liabilities and stockholders’ equity	$ 56.5	$ 72.7

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2016	Jun. 30, 2016
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	38,640,487	38,640,487
Common stock, shares outstanding (in shares)	38,640,487	38,640,487

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Royalty revenue	$ 1.5	$ 1.7	$ 1.6	$ 3.4
Non-cash royalty revenue related to the sale of future royalties	2.3		2.3
Total revenue	3.8	1.7	3.9	3.4
Operating expense:
Research and development	10.2	6.3	17.8	11.8
General and administrative	2.1	2.1	4.3	4.4
Foreign exchange (gain) loss, net	0.1	(0.2)		0.5
Total operating expense	12.4	8.2	22.1	16.7
Loss from operations	(8.6)	(6.5)	(18.2)	(13.3)
Other (expense) income:
Non-cash interest expense on liability related to sale of future royalties	(0.5)		(0.9)
Interest income	0.1		0.1	0.1
Total other (expense) income	(0.4)		(0.8)	0.1
Loss before tax	(9.0)	(6.5)	(19.0)	(13.2)
Income tax expense	0.1		0.1
Net loss	$ (9.1)	$ (6.5)	$ (19.1)	$ (13.2)
Basic and diluted net loss per share (in dollars per share)	$ (0.24)	$ (0.17)	$ (0.49)	$ (0.34)
Basic and diluted weighted-average shares outstanding (in shares)	38,640,487	38,636,946	38,640,487	38,630,587

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Dec. 31, 2016 - USD ($) $ in Millions	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Jun. 30, 2016	38,640,487				38,640,487
Balances at Jun. 30, 2016	$ 3.9	$ 157.6	$ (134.3)	$ 19.0	$ 46.2
Net loss			(19.1)		(19.1)
Share-based compensation		0.9			$ 0.9
Balances (in shares) at Dec. 31, 2016	38,640,487				38,640,487
Balances at Dec. 31, 2016	$ 3.9	$ 158.5	$ (153.4)	$ 19.0	$ 28.0

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (19.1)	$ (13.2)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	0.9	1.2
Non-cash interest expense related to sale of future royalties	0.9
Non-cash royalty revenue related to sale of future royalties	(2.3)
Change in operating assets and liabilities:
Accounts receivables	(1.4)	7.5
Prepaid expenses and other current assets	(0.1)	(0.9)
Accounts payable and accrued expenses	1.4	(2.8)
Net cash used in operating activities	(19.7)	(8.2)
Cash flows from investing activities:
Purchases of short and long-term investments	(8.4)	(6.4)
Maturity of short-term investments	16.6	9.0
Net cash provided by investing activities	8.2	2.6
Cash flows from financing activities:
Payment on note payable	(0.1)	(0.1)
Net cash used in financing activities	(0.1)	(0.1)
Decrease in cash and cash equivalents	(11.6)	(5.7)
Cash and cash equivalents at beginning of period	49.7	44.7
Cash and cash equivalents at end of period	$ 38.1	$ 39.0

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Company Overview	6 Months Ended
Note 1 - Company Overview	Dec. 31, 2016
Notes to Financial Statements
Nature of Operations [Text Block]	1) Company Overview Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has four Phase 2 clinical programs: vapendavir, an oral treatment for rhinovirus (RV) upper respiratory infections in moderate-to-severe asthmatics; vapendavir, for the treatment of RV infections in hematopoietic stem cell transplant patients; BTA585, an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus ("RSV") infections; and BTA074, a topical antiviral treatment for condyloma caused by human papillomavirus types 6 & 11. The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia. Although several of the Company ’s influenza product candidates have been successfully developed and commercialized to date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any product candidates that it is developing now, or may develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates. The Company plans to continue to finance its operations with (i) existing cash, cash equivalents and investments, (ii) proceeds from existing or potential future royalty-bearing licenses or collaborative research and development arrangements, (iii) future equity and/or asset or debt financings, or (iv)other financing arrangements. The Company ’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources, continuing to receive royalty revenue under existing licenses, entering into future collaboration, license or commercialization agreements, the successful development of its product candidates, executing future financings and ultimately, upon the approval of its products for sale and achieving positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to the Company, if at all, that the Company will be able to enter into collaboration, license or commercialization agreements in the future, or that the Company will ever generate significant product revenue and become operationally profitable on a consistent basis.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation	6 Months Ended
Note 2 - Basis of Presentation	Dec. 31, 2016
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	(2) Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the condensed consolidated financial statements included in the Company’s Annual Report on Form 10 -K that was filed with the SEC on September 13, 2016. The unaudited interim condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation. Operating results for the three and six months ended December 31, 2016 are not necessarily indicative of those in future quarters or the annual results that may be expected for the Company’s fiscal year ending June 30, 2017. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2016 included in the Company’s Annual Report on Form 10 -K. The Company ’s significant accounting policies have not changed since June 30, 2016. Recent Accounting Standards In May 2014, the Financial Accounting Standards Board ("FASB") issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods b eginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements. In August 2014, the FASB issued authoritative accounting guidance related to management ’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for annual reporting ending after December 15, 2016, and for annual periods and interim periods thereafter, with early application permitted. Accordingly, the standard is effective for the Company on June 30, 2017. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements. In February 2016, the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements. In March 2016, the FASB issued guidance on stock compensation. This guidance simplifies the accounting for the taxes related to stock based compensation, including adjustments to how excess tax benefits and a company's payments for tax withholdings should be classified. The guidance is effective for public companies for annual periods, and interim periods within those annual periods, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact that the guidance will have on the consolidated financial statements. In August 2016, the FASB issued new guidance on how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for the Company beginning July 1, 2018. Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements. In January 2017, the FASB amended and clarified guidance related to b usiness combinations and the definition of a business. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Accordingly, the amendments are effective for the Company beginning July 1, 2018. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Fair Value Disclosures [Text Block]

(3)

Fair Value Measurements

A fair value hierarchy has been established

that requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes

three

levels of inputs that

may

be used to measure fair value:

	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at

December

31,

2016

and

June

30,

2016,

by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

he Company’s short-term investments have been classified as Level

which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a

third

party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications.

			Quoted Prices in		Significant
			Active Markets		Other		Significant
(in millions)			for Identical Assets		Observable Inputs		Unobservable Inputs
December 31 , 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	10.7	$	7.7	$	3.0	$	—
Short-term investments available-for-sale		11.1		—		11.1		—
Total	$	21.8	$	7.7	$	14.1	$	—

			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for Identical		Observable		Unobservable
(in millions)			Assets		Inputs		Inputs
June 30, 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	1.5	$	1.5	$	—	$	—
Short-term investments available-for-sale	19.3			10.0		9.3		—
Total	$	20.8	$	11.5	$	9.3	$	—

365

days from the date of acquisition.

The following table shows the unrealized gains and losses and fair values for those investments as of

December

31,

2016

and

June

30,

2016

aggregated by major security type:

(in millions)			Unrealized		Unrealized
December 31 , 201 6	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	7.7	$	-	$	-		7.7
Corporate notes		9.4		-		-		9.4
Commercial paper		3.0		-		-		3.0
Certificates of deposit		1.7		-		-		1.7
Total	$	21.8	$	-	$	-		21.8

(in millions)			Unrealized		Unrealized
June 30, 201 6	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	1.5	$	—	$	—	$	1.5
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		7.0		—		—		7.0
Corporate notes		2.9		0.1		—		3.0
Certificates of deposit		7.3		—		—		7.3
Total	$	20.7	$	0.1	$	—	$	20.8

As of

December

31,

2016,

the Company had no investments in an unrealized gain (loss) position.

As of

June

30,

2016,

the Company had investments in an unrealized gain position. The Company has determined that the unrealized gains on these investments are temporary in nature and expects the security to mature at its stated maturity principal. All available-for-sale securities held at

December

31,

2016,

will mature within a

one

year period. The fair value of cash, accounts receivable, accounts payable and accrued liabilities approximate their carrying value because of the short-term nature of these financial instruments respectively, at

December

31,

2016

and

June

30,

2016.

The fair value of the Company’s short-term note payable, which is measured using Level

inputs, approximates book value, at

December

31,

2016

and

June

30,

2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Accrued and Other Current Liabilities

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(4)

Accrued

and Other Current Liabilities

Accrued

expenses consist of the following (in millions):

	December 31 , 201 6		June 30, 201 6

Professional fees	$	0.5	$	0.1
Salary and benefits		0.5		0.6
Research and development expenses		4.6		2.2
Other accrued expenses		-		0.7
Total accrued expenses and other liabilities	$	5.6	$	3.6

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Liabilities Related to Sale of Future Royalties

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Deferred Revenue Disclosure [Text Block]

(

Liabilities Related to Sale of Future Royalties

April

2016,

the Company sold certain royalty rights related to the approved product Inavir

, sold by Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in the Japanese market, for

$20

million to HealthCare Royalty Partners III, L.P. (“HCRP”). Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the arrangement, this transaction was accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. As of

December

31,

2016

and

June

30,

2016,

the amount receivable from Daiichi Sankyo related to the HCRP transaction was

$2.2

million and

$0.2

million, respectively, which has been included in “Accounts Receivable” in the accompanying condensed consolidated balance sheets.

In order to record the amortization of the liability, the Company is requir

ed to estimate the total amount of future royalty payments to be received under the License Agreement with Daiichi Sankyo and the payments that will be passed through to HCRP over the life of the agreement. The sum of the pass through amounts less the net proceeds received will be recorded as non-cash interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The Company will periodically assess the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company will adjust the amortization of the liability and interest rate. As a result of this accounting, even though the Company does not retain HCRP’s share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability and related interest is fully amortized

The following table shows the activity within the liability account during the

six

months ended

December

31,

2016:

	in millions
Total Liability related to sale of future royalties, June 30, 201 6	$	18.1
Non-cash royalty revenue paid to HCRP		(0.2	)
Non-cash interest expense recognized		0.9
Total Liability related to sale of future royalties, December 31, 2016	$	18.8

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Net Loss Per Share

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Earnings Per Share [Text Block]

) Net Loss per share

Basic and diluted

net loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and unvested restricted stock units) are excluded from the calculation as their inclusion would be anti-dilutive. The Company has excluded all anti-dilutive share-based awards to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following table

s set forth the computation of historical basic and diluted net loss per share.

	Three Months Ended December 31 ,
	201 6			201 5

Net loss (in millions)	$	(9.1	)	$	(6.5	)
Weighted-average shares outstanding		38,640,487			38,636,946
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,636,946
Basic net loss per share	$	(0.24	)	$	(0.17	)
Diluted net loss per share	$	(0.24	)	$	(0.17	)
Number of anti-dilutive share-based awards excluded from computation		5,645,543			4,631,556

	Six Months Ended December 31 ,
	201 6			201 5

Net loss (in millions)	$	(19.1	)	$	(13.2	)
Weighted-average shares outstanding		38,640,487			38,630,587
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,630,587
Basic net income (loss) per share	$	(0.49	)	$	(0.34	)
Diluted net loss per share	$	(0.49	)	$	(0.34	)
Number of anti-dilutive share-based awards excluded from computation		5,645,543			4,619,210

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements

6 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Collaborative Arrangement Disclosure [Text Block]

)

Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with

GlaxoSmithKline (“GSK”) in

1990

for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as Relenza® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and has been entitled to receive royalty payments of

of GSK's annual net sales of Relenza

in the U.S., Europe, Japan and certain other countries as well as

10%

of GSK's annual net sales of Relenza

in Australia, New Zealand, South Africa and Indonesia. Most of the Company’s Relenza

patents have expired and the only substantial remaining intellectual property related to the Relenza

patent portfolio is scheduled to expire in

July

2019

in Japan.

The Company also generates royalty revenue from the sale of Inavir

(laninamivir octanoate or LANI) in Japan, pursuant to a collaboration and license agreement and a related commercialization agreement (collectively, the “Inavir License Agreement”) with Daiichi Sankyo. In

September

2010,

Inavir

was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children. Under the Inavir License Agreement, the Company currently receives a

royalty on net sales of Inavir

in Japan and is eligible to earn sales milestone payments. Under the Inavir License Agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any

third

party licenses outside of Japan. Patents on the composition of matter for LANI in Japan generally expire in

2024.

April

2016,

the Company entered into a Royalty Interest Acquisition Agreement (“Agreement”) with HCRP. Under the Agreement, HCRP made a

$20

million cash payment to the Company in consideration for acquiring from the Sellers certain royalty rights (“Royalty Rights”) related to the approved product Inavir

in the Japanese market. The Royalty Rights were obtained pursuant to the Inavir License Agreement.

The following tables summarize the key components of the Company

’s revenues (in millions):

	Three Months Ended December 31 ,
	2016		2015
	(in millions)
Royalty revenue - Relenza ®	$	1.5	$	1.0
- Inavir ®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.8	$	1.7

	Six Months Ended December 31 ,
	2016		2015
	(in millions)
Royalty revenue - Relenza ®	$	1.6	$	2.7
- Inavir ®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.9	$	3.4

Collaborative and contract arrangements

July

2016,

the Company entered into an exclusive, worldwide license for RSV replication inhibitors intellectual property with Georgia State University Research Foundation (“GSURF”) in exchange for an upfront fee, future milestone payments and royalties on future net sales of any products that utilize the underlying RSV intellectual property. The Company has an obligation to make a minimum payment of

$10,000

to GSURF annually until the license agreement expires or is terminated. The Company also entered into a

two

year sponsored research agreement with GSURF for annual sponsored research payments.

In connection with the Company

’s

BTA585

clinical trial, a Clinical Research Organization (“CRO”), engaged by the Company to provide certain services for this trial, notified the Company of its intent to explore additional compensation due to a previous delay in the trial. In

December

2016,

the Company and the CRO agreed to a settlement and the Company’s insurance carrier agreed to reimburse the Company for the amount of the settlement, less its deductible.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Share-based Compensation	6 Months Ended
Note 8 - Share-based Compensation	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	( 8 ) Share-based Compensation On November 10, 2016, our stockholders approved the 2016 Equity Incentive Plan (“ 2016 Equity Plan”), under which a total of 4,794,137 shares may be available for issuance. The 2016 Equity Plan replaced and superseded our amended 2007 Omnibus Equity and Incentive Plan (“Prior Plan”). In addition, under the 2016 Equity Plan all outstanding awards under the Prior Plan will become available for issuance under the 2016 Equity Plan if such awards are forfeited or otherwise terminate. For the three month period ended December 31, 2016 and 2015, the Company recorded share-based compensation expense related to grants from equity incentive plans of $0.5 million and $0.6 million, respectively. For the six month period ended December 31, 2016 and 2015, the Company recorded share-based compensation expense related to grants from equity incentive plans of $0.9 million and $1.2 million, respectively. No income tax benefit was recognized in the statements of operations and no share-based compensation expense was capitalized as part of any assets for the three month and six month periods ended December 31, 2016 and 2015.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the condensed consolidated financial statements included in the Company’s Annual Report on Form 10 -K that was filed with the SEC on September 13, 2016. The unaudited interim condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation. Operating results for the three and six months ended December 31, 2016 are not necessarily indicative of those in future quarters or the annual results that may be expected for the Company’s fiscal year ending June 30, 2017. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2016 included in the Company’s Annual Report on Form 10 -K. The Company ’s significant accounting policies have not changed since June 30, 2016.
Basis of Accounting, Policy [Policy Text Block]	Recent Accounting Standards In May 2014, the Financial Accounting Standards Board ("FASB") issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods b eginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements. In August 2014, the FASB issued authoritative accounting guidance related to management ’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for annual reporting ending after December 15, 2016, and for annual periods and interim periods thereafter, with early application permitted. Accordingly, the standard is effective for the Company on June 30, 2017. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements. In February 2016, the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements. In March 2016, the FASB issued guidance on stock compensation. This guidance simplifies the accounting for the taxes related to stock based compensation, including adjustments to how excess tax benefits and a company's payments for tax withholdings should be classified. The guidance is effective for public companies for annual periods, and interim periods within those annual periods, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact that the guidance will have on the consolidated financial statements. In August 2016, the FASB issued new guidance on how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for the Company beginning July 1, 2018. Early adoption is permitted. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements. In January 2017, the FASB amended and clarified guidance related to b usiness combinations and the definition of a business. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Accordingly, the amendments are effective for the Company beginning July 1, 2018. We do not expect the adoption of this guidance to have a material impact on the consolidated financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Quoted Prices in		Significant
			Active Markets		Other		Significant
(in millions)			for Identical Assets		Observable Inputs		Unobservable Inputs
December 31 , 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	10.7	$	7.7	$	3.0	$	—
Short-term investments available-for-sale		11.1		—		11.1		—
Total	$	21.8	$	7.7	$	14.1	$	—

			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for Identical		Observable		Unobservable
(in millions)			Assets		Inputs		Inputs
June 30, 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	1.5	$	1.5	$	—	$	—
Short-term investments available-for-sale	19.3			10.0		9.3		—
Total	$	20.8	$	11.5	$	9.3	$	—

Unrealized Gain (Loss) on Investments [Table Text Block]

(in millions)			Unrealized		Unrealized
December 31 , 201 6	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	7.7	$	-	$	-		7.7
Corporate notes		9.4		-		-		9.4
Commercial paper		3.0		-		-		3.0
Certificates of deposit		1.7		-		-		1.7
Total	$	21.8	$	-	$	-		21.8

(in millions)			Unrealized		Unrealized
June 30, 201 6	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	1.5	$	—	$	—	$	1.5
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		7.0		—		—		7.0
Corporate notes		2.9		0.1		—		3.0
Certificates of deposit		7.3		—		—		7.3
Total	$	20.7	$	0.1	$	—	$	20.8

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 4 - Accrued and Other Current Liabilities (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	December 31 , 201 6		June 30, 201 6

Professional fees	$	0.5	$	0.1
Salary and benefits		0.5		0.6
Research and development expenses		4.6		2.2
Other accrued expenses		-		0.7
Total accrued expenses and other liabilities	$	5.6	$	3.6

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 5 - Liabilities Related to Sale of Future Royalties (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

	in millions
Total Liability related to sale of future royalties, June 30, 201 6	$	18.1
Non-cash royalty revenue paid to HCRP		(0.2	)
Non-cash interest expense recognized		0.9
Total Liability related to sale of future royalties, December 31, 2016	$	18.8

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 6 - Net Loss Per Share (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended December 31 ,
	201 6			201 5

Net loss (in millions)	$	(9.1	)	$	(6.5	)
Weighted-average shares outstanding		38,640,487			38,636,946
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,636,946
Basic net loss per share	$	(0.24	)	$	(0.17	)
Diluted net loss per share	$	(0.24	)	$	(0.17	)
Number of anti-dilutive share-based awards excluded from computation		5,645,543			4,631,556

	Six Months Ended December 31 ,
	201 6			201 5

Net loss (in millions)	$	(19.1	)	$	(13.2	)
Weighted-average shares outstanding		38,640,487			38,630,587
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,630,587
Basic net income (loss) per share	$	(0.49	)	$	(0.34	)
Diluted net loss per share	$	(0.49	)	$	(0.34	)
Number of anti-dilutive share-based awards excluded from computation		5,645,543			4,619,210

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Tables)

6 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended December 31 ,
	2016		2015
	(in millions)
Royalty revenue - Relenza ®	$	1.5	$	1.0
- Inavir ®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.8	$	1.7

	Six Months Ended December 31 ,
	2016		2015
	(in millions)
Royalty revenue - Relenza ®	$	1.6	$	2.7
- Inavir ®		-		0.7
Non-cash royalty revenue related to the sale of future royalties		2.3		-
Total revenue	$	3.9	$	3.4

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements (Details Textual)	6 Months Ended
Note 3 - Fair Value Measurements (Details Textual)	Dec. 31, 2016
Available-for-Sale Securities, Maturity Period	1 year

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements - Summary of Investments (Details) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 30, 2016
Available for Sale Securities - Current	$ 21.8	$ 20.8
Total	21.8	20.8
Fair Value, Inputs, Level 1 [Member]
Total	7.7	11.5
Fair Value, Inputs, Level 2 [Member]
Total	14.1	9.3
Fair Value, Inputs, Level 3 [Member]
Total
Cash Equivalents [Member]
Available for Sale Securities - Current	10.7	1.5
Cash Equivalents [Member] \| Fair Value, Inputs, Level 1 [Member]
Available for Sale Securities - Current	7.7	1.5
Cash Equivalents [Member] \| Fair Value, Inputs, Level 2 [Member]
Available for Sale Securities - Current	3.0
Cash Equivalents [Member] \| Fair Value, Inputs, Level 3 [Member]
Available for Sale Securities - Current
Short-term Investments [Member]
Available for Sale Securities - Current	11.1	19.3
Short-term Investments [Member] \| Fair Value, Inputs, Level 1 [Member]
Available for Sale Securities - Current		10.0
Short-term Investments [Member] \| Fair Value, Inputs, Level 2 [Member]
Available for Sale Securities - Current	11.1	9.3
Short-term Investments [Member] \| Fair Value, Inputs, Level 3 [Member]
Available for Sale Securities - Current

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurements - Unrealized Gain (Loss) on Investments (Details) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 30, 2016
At Cost	$ 21.8	$ 20.7
Unrealized Gains		0.1
Unrealized (Losses)
Fair Value	21.8	20.8
Money Market Funds [Member]
At Cost	7.7	1.5
Unrealized Gains
Unrealized (Losses)
Fair Value	7.7	1.5
Corporate Note Securities [Member]
At Cost	9.4	2.9
Unrealized Gains		0.1
Unrealized (Losses)
Fair Value	9.4	3.0
US Government Agencies Debt Securities [Member]
At Cost		2.0
Unrealized Gains
Unrealized (Losses)
Fair Value		2.0
Commercial Paper [Member]
At Cost	3.0
Unrealized Gains
Unrealized (Losses)
Fair Value	3.0
US Treasury Securities [Member]
At Cost		7.0
Unrealized Gains
Unrealized (Losses)
Fair Value		7.0
Certificates of Deposit [Member]
At Cost	1.7	7.3
Unrealized Gains
Unrealized (Losses)
Fair Value	$ 1.7	$ 7.3

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 4 - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 30, 2016
Professional fees	$ 0.5	$ 0.1
Salary and benefits	0.5	0.6
Research and development expenses	4.6	2.2
Other accrued expenses		0.7
Total accrued expenses and other liabilities	$ 5.6	$ 3.6

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 5 - Liabilities Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2016	Dec. 31, 2016	Jun. 30, 2016
HealthCare Royalty Partners III, L.P. [Member] \| Royalty Arrangement [Member]
Deferred Revenue, Additions	$ 20.0
Daiichi Sankyo [Member]
Accounts Receivable, Net		$ 2.2	$ 0.2

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 5 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - Royalty Arrangement [Member] - HealthCare Royalty Partners III, L.P. [Member] $ in Millions	6 Months Ended
	Dec. 31, 2016 USD ($)
Total Liability related to sale of future royalties, June 30, 2016	$ 18.1
Non-cash royalty revenue paid to HCRP	(0.2)
Non-cash interest expense recognized	0.9
Total Liability related to sale of future royalties, December 31, 2016	$ 18.8

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Net Loss Per Share - Computation of Historical Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (9.1)	$ (6.5)	$ (19.1)	$ (13.2)
Weighted-average shares outstanding (in shares)	38,640,487	38,636,946	38,640,487	38,630,587
Shares used to compute diluted earnings per share (in shares)	38,640,487	38,636,946	38,640,487	38,630,587
Basic net loss per share (in dollars per share)	$ (0.24)	$ (0.17)	$ (0.49)	$ (0.34)
Diluted net loss per share (in dollars per share)	$ (0.24)	$ (0.17)	$ (0.49)	$ (0.34)
Number of anti-dilutive share-based awards excluded from computation (in shares)	5,645,543	4,631,556	5,645,543	4,619,210
Basic net income (loss) per share (in dollars per share)	$ (0.24)	$ (0.17)	$ (0.49)	$ (0.34)
Diluted net loss per share (in dollars per share)	$ (0.24)	$ (0.17)	$ (0.49)	$ (0.34)

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Details Textual) - USD ($)		6 Months Ended
	Apr. 22, 2016	Dec. 31, 2016
HealthCare Royalty Partners III, L.P. [Member]
Proceeds From Sale of Royalty Rights, Gross	$ 20,000,000
Georgia State University Research Foundation (GSURF) [Member]
Collaborative Arrangement, Annual Minimum Payment		$ 10,000
United States, Europe, Japan, And Other Countries [Member] \| GSK [Member]
Royalty Payment Percentage		7.00%
Australia, New Zealand, South Africa, and Indonesia [Member] \| GSK [Member]
Royalty Payment Percentage		10.00%
Japan [Member] \| Daiichi Sankyo [Member]
Royalty Payment Percentage		4.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements - Components of Revenues From Royalties, Collaborative and Contractual Agreements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Royalty revenue	$ 1.5	$ 1.7	$ 1.6	$ 3.4
Non-cash royalty revenue related to the sale of future royalties	2.3		2.3
Total revenue	3.8	1.7	3.9	3.4
Relenza [Member]
Royalty revenue	1.5	1.0	1.6	2.7
Inavir [Member]
Royalty revenue		$ 0.7		$ 0.7

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 8 - Share-based Compensation (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Nov. 10, 2016
Allocated Share-based Compensation Expense	$ 500	$ 600	$ 900	$ 1,200
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	0	0	0	0
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$ 0	$ 0	$ 0	$ 0
The 2016 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					4,794,137

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #9Y1DH?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ -GE&2F;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " V>49*P+94JO K @ $0 &1O8U!R;W!S+V-O M&ULS9+/3L,P#(=?!>7>.NVT 5&7"]-.("$Q"<0M2KPMHOFCQ*C=V].6 MK1."!^ 8^Y?/GR4W.@H=$CZG$#&1Q7S3N]9GH>.:'8FB ,CZB$[ED/=4"H.5^!0U)&D8(16,29R&1CM- )%85TQAL]X^-G:B>8T8 M M.O24H2HK8'*<&$]]V\ 5,,((D\O?!30S<:K^B9TZP,[)/MLYU75=V2VFW+!# M!6]/CR_3NH7UF937./S*5M IXII=)K\N'C:[+9,UKVX+7A=\M:N6@M^)Y?W[ MZ/K#[RKL@K%[^X^-+X*R@5]W(;\ 4$L#!!0 ( #9Y1DJ97)PC$ 8 )PG M 3 >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&V MM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X M>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E M'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ( MX53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T M;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW? MZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;C MZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6 M-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[ MR:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>I MP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^ M",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ M ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH M9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-# MMW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX# M;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW' MB/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$" M\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO* MWF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4" M(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8> M^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@ M#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6: M&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+ MOP%02P,$% @ -GE&2J6DL!N' @ 10D !@ !X;"]W;W)KOOT/,!99I@ M$#]J.HA%V].IG!A[U9W/EZT?ZAG1AIZE#D'4ZT$/M&ET)#6/7U-0?];4Q&7[ M/?I'D[Q*YD0$/;#F9WV1U=;/?>]"K^3>R!B=(X MLT:8IW>^"\G:*8J:2DO>QG?=F?"+@F8#S_Q*BB1#-!!2;Y,>9 MF50_$$G*@K/!X^/?ZHDN"O0Q; D, >.W3\K\#!142P0 1F$!EZM*#',#T&Z;&AQPMZ8BV BTAA@004 M2!QZ9@F,B,0@NA&!XW@EBQ0421V1W!)Q$1M8( ,%,H>.[$(!("N5DH,2N C#9BLJ*;Y$;P?[E$&9-!33O M#F$WPL:R[X19EF^4I_$&1VM:L(]1Y&AA9R\","LUAF"[(]?-V*XR"+-29@CV M/')-C^U"0Z[M<;CZ?V#;(]?5V-Z^)DRZQ*QL8 CV/G*=C>T]#,+DEDJP.)1: MRF_F_!;>F=T[49*WS4T M1*D# ""$0 & 'AL+W=OJTI?UC[SWR\\EL>3 MZ2^$F]6Y.*H?ROP\/[3V++RVLB]KU72E;KQ6'=;^1W:WC:,^8%#\*M6EFQU[ M?2I/6C_W)U_W:S_J':E*[4S?1&%WKVJKJJIOR?KX,S7J7_OL ^?'[ZU_'I*W MR3P5G=KJZG>Y-Z>UG_G>7AV*E\H\ZLL7-24D?6_*_IMZ5965]TYL'SM==<.O MMWOIC*ZG5JR5NG@;]V4S["]3^^]A= "? O@U@(F; ?$4$(. <'0VI/JI,,5F MU>J+UXZC=2[Z2<'N8EO,77]QJ-WPG\VVLU=?-SQ?A:]].Y/D?I3PN62IV&)% M'%TEH>W_:H*3)O@0'\_C&1T?D_'Q$"_F\<#B_2A)!TDS2K* @3RP2.1!2CL1 MI!.!G<3 R2C)9ITPAIP0HCR(:2>2="*Q$P&<2-2)".#08DWDJDA"^DBP#PE\ M)*@/'F3 !Z5Q^$A)'RGVD0 ?*>I#)J@@6)3R0$2SS3%U,])6AJ>^(ZV*$9QS#D!(00(BCV&>L13?#80JF3UY MEBL7&GL<8T] ['$,-%R9_XB67FCH<8:\R AZ8?A!FJ$I2*GFH%ZZ<2SJ,$ E M!"BE086YJ5DZH?')8S3_I6/.<1IZ'$-/0M!0&I3+3J&1QS'R)%Q3<0)YDIAPE"QU/9HXS3F.UW@24FK2R,7*&IJYJ5DZ MH7G),2\E9!3'*/S )%X_D+I8N*C):6IR3$V).)6CO#EB/99-YSUI8]^KA[??@]9&V1;MT]CW M3JK87T\J=3#]86J/V_&KP'AB]'GZXA%>/[ML_@%02P,$% @ -GE&2@'X M$?0I @ 90< !@ !X;"]W;W)K0">\PY,]\0 MR\XZRMYX"2"<]YHT?.N60K0;A/BQA!KS%]I"(]^<*:NQD"&[(-XRP"=MJ@GR M/2]&-:X:-\_TVI[E&;T*4C6P9PZ_UC5F_W9 :+=U5^Y]X;6ZE$(MH#QK\05^ M@OC5[IF,T)CE5-70\(HV#H/SUOVTVA2ITFO![PHZ/ID[JI,#I6\J^';:NIX" M @)'H3)@.=R@ $)4(HGQ=\CICB65<3J_9_^B>Y>]'#"'@I(_U4F46S=QG1.< M\96(5]I]A:&?R'6&YK_##8B4*Q)9XT@)UT_G>.6"UD,6B5+C]WZL&CUV0_Z[ M;=G@#P9_-*S"AX9@, 2& ?5DNM7/6. \8[1S6/]GM5CMB=4FD!_SJ!;UM]/O M9+=)6AF\HS2':]Q)](_+FBL!6!-TJ0K#]"^(L0OO:'4PBCQ*Z7I%K2 M:(GW8H 6CS4SCF"1([ Y H.CET23&I&G?P;+Q[H93[C($]H\H<$36G5,DD>* M&4.TR!#9#)'!$'W(\$@Q8X@7&6*;(388XB?VQV/-C&.]R+&V.=8&Q]KJU/>\ MQ1WRC'+&E"PR)3938C E5J4@B4,O3 SXX@GAC"A=)$IMHM0@2I\E>D+8$Z') M@:&PO=V]R:W-H M965T&ULC5C;CJ,X$/T5Q/L"-C<3)9$Z":M=:5=JS6AWGNG$ M2= SH#3F?W[-9=.0U6123]TP#EURJ?*Y@0O;ZK^WIREU-;/LJB:E7W6^K)P MW69_EF76..HB*_/-4=5EILUM?7*;2RVS0Q=4%B[WO,@ML[RRU\MN[+5>+]55 M%WDE7VNKN99E5O^WD86ZK6QF?PQ\R4]GW0ZXZ^4E.\FO4O]S>:W-G7MG.>2E MK)I<558MCRO[A2U2W@5TB']S>6M&UU8KY4VI[^W-GX>5[;4SDH7KAD M[;)CB]"T:]\.=MWIOC/U;,SH^SKVENY[RS- -CV$CR%L"MEAR"?"-?GOD^#4 M)#8)^.#\CXH(L/QO$!J'4/B3M( MU1?2"4$M*$P,BD%A(E .C/&=@-83DGI"K ?,==-#Q"@'=WR@!].$L+=/T*0/ M:29J(E)-A-6 BFTB- W?$4 -QN#N4#P)D$-A9KH3DWIBO%IC.EZ0\0+7 VC= M"*S5<^#6Q: (]FY'$,6PLBD!8B/01%)"2DJP)%#V34*L-/"TVSZ!V6%,@%8L MA9EI,?/HI[>'% GT^/90&@])(D"_H5;NB'1PJZ9DNG!&U8PG,:R*054,KP;N M!% 61@F')9,_J!&'<-3>E$H?.3/[BY&N]\(XELFA3([[(N"3?$NA(N@;.PK% M!&QR2L)\9\;I&&V5#'NEF&.@S9)AMQ30+0<,6+70+PDF9# T$WPF/V::JJ(M MDV&7$M S&78[8L,^X9K/$*6_ $U%T<[)L'4*:)T,^YDI,-JOF FK(IF@61"H M>5FT@;(8RXJAK!X3CB>30%'Q4[N38&)H 1)49F_.K4':V!EV=@&=G6&S)=8@ M)L+=>H(H?4PTU40[.\/6+J"U#YAXTBLLBD 1W2)0#)&E)&RV7YPV>8Y=-X$F M/V 2X-]P?]$P!G^?TK KD8:YL_\A.&TV7-L]@DT^P$SWAN^B (O@/MQ2R/] M* DBJ/%9SG2&TPL%]'MW]-9=ROK4'8$TUEY=*]V:X6CT?LSRPMNW=C"^88LM M(\9W;)'VARB?]/V9SM]9?Z,_*J6E$6 &PO=V]R:W-H965T&ULC9;9CML@%(9?Q?+]>-\2.9:: M3:W42M&,VEZ3A,368.,"2:9O7\#$8V.4YB8L_OYS_@,(DM\P>:$C]P^RK&J M84,KW%@$GA;V%W^^304O@5\5O-%!WQ*5[#%^%X-OQX7M"4,0P0,3$0!OKG % M$1*!N(T_*J;=IQ3"8?\>?2MKY[7L 84KC'Y71U8N[,RVCO $+HB]XMM7J.J) M;4L5_QU>(>*X<,)S'#"B\M<*W]R FY6[*;WS]*9^]%K,@=Z\BCD*6'1(,D7",K Q(-$;6!B0> M(QL#DHR1K0%)>\3EE?;E!L9R ZF/AOI,*[=#8HDT$@FS)/*B+-6\/ &.'(5& M1^'4T4QSU"'I,)&C,:LIX\>IHRW?>DJ]^&'D:-NYZ3#?&T;3$FZGH:+$",'V>.=@FLI]2+'X>.=IUL MTB>.J($),JUR=W!1BJ?T!R#GJJ'6'C-^YY_"5+/GKW0\0/#'1 M37F?=&]8-V"X5<^SV_]'*/X!4$L#!!0 ( #9Y1DKNZ7R510, -(- 8 M >&PO=V]R:W-H965T&ULC5?1;ILP%/T5Q'N!:R! E41J M,DV;M$E5IVW/-'$25, ,G*3[^]F&4+"OU^8A@'/N\3FV.;&75]:^="=*N?-: ME76W^W^U.M,H[CS6T%K\<6%OE7#RV1[]K6IKO55%5^B0(%GZ5%[6[ M7JJVQW:]9&=>%C5];)WN7%5Y^W=#2W9=N>#>&IZ*XXG+!G^];/(C_4'YS^:Q M%4_^R+(O*EIW!:N=EAY6[@/<;TDH"Q3B5T&OW>3>D5:>&7N1#U_W*S>0BFA) M=UQ2Y.)RH5M:EI))Z/@SD+ICG[)P>G]C_ZS,"S//>4>WK/Q=[/EIY::NLZ>' M_%SR)W;]0@=#L>L,[K_1"RT%7"H1?>Q8V:EO9W?N.*L&%B&ERE_[:U&KZW7@ MOY7A!60H(&.!Z/M_!>%0$+X51,I\KTQ9_93S?+ULV=5I^]EJ \A M:B)4]>',1(031"A!I BB"4&::8/00Q(%J17D#C(/-"<8*O0L9F)42XR8B7&" M!4JP,,Q $&AN>DPZT1EXFN.MB0&;DP05DB!"%IJ0Y -"3)[8HB-%=:2(CD33 MD1HZ[HBGO0A;D\@F)$.%9,C4IC@!!/CK&B!>]*4Z@&9FP(LT,P@J\2P+#2SA M :8:T)?: )JI"8P7!T=E%CEHT#P 0>2 +H<@R]H8&Q,DEH-MJO!0@A!10W0U M(3)5F9?H>A!8ZD$V^UC4X8D'D;D6(;10X$$%,6(PT@W&F')CO!'4PK-$.."Q M!TCN0:S+04)MX2UT.3TJGJ!LHXLG'R#1!WKT@9E]]CD=A)DE9*)^+@T/0TB1 MB4\L%'B,08:X2W5WV8=>^W=0\^T%GHD$R430,Y$@F6C*>0\UEX.'(D%"D>BA M2)"X S 6(@:+/9,80AHJL6><](Z'DP>B-Q):^T;<6#ICQ=O M-/UIYWO>'HNZ&PO=V]R M:W-H965T&UL;5-A;]P@#/TKB!]0[DC:5:/*J5>=RVGK?'QAS90M: MN"O30X#1MPUQO0501I!7CN]T-TT)VM,BB[V2+S Q>R0Y.EKA!:V'? MCJ#,F-,]?7<\R:;UP<&*K!<-_ 3_JS]9M-C"4DD-G9.F(Q;JG-[M#\ MWQ)&MSJ34,G9F.=@/%0YW05!H*#T@4'@=H%[4"H0H8R7F9,N*0-P?7YG_Q9K MQUK.PL&]47]DY=NJXIF8O_ 1=0&!Z48([2*!=74@[. M&SVSH!0M7J===G$?IYLDG6'; #X#^ *XC7G8E"@J_RJ\*#)K1F*GWORGV/,G8)1#-,<'S9V/_:& \H97>%(]3B!UL,!;4/QR]XMM.8388W_?R# MV/*-B[]02P,$% @ -GE&2B&(]52V 0 T@, !@ !X;"]W;W)KTW3)FVRN:;M9U9' M)0=B =?KO^^ GO6N?@%FF/?FS3!DH[%/K@7PY%FKSN6T];X_,>;*%K1P=Z:' M#F]J8[7P:-J&N=Z"J")(*\9WN_=,"]G1(HN^BRTR,W@E.[A8X@:MA?US!F7& MG";TQ?$HF]8'!RNR7C3P'?R/_F+18@M+)35T3IJ.6*AS>I^4?)7/Q7N('"\* $Z)D% MI6CQ/.VRB_LXW1R2&;8-X#. +X!CS,.F1%'Y1^%%D5DS$COUOA?AB9,3Q]Z4 MP1E;$>]0O$/OK4CX(6.W0#3'G*<8OHY9(ABR+RGX5HHS_P_.M^'[387["-^_ M4IAN$Z2;!&DD2%\1'-^4N!7SX4T2MNJI!MO$:7*D-$,7)WGE70;VGLW#\8!G.XW99'C3SS^(+=^X M^ M02P,$% @ -GE&2@O45KJU 0 T@, !@ !X;"]W;W)KI-"V1+WS@T'0FS=@V3V2@^@_$VK MC63.FZ8C=C# F@B2@M DN2&2<86K(OI.IBKTZ 17<#+(CE(R\WX$H:<2I_C# M\<*[W@4'J8J!=? =W(_A9+Q%5I:&2U"6:X4,M"6^2P_'/,3'@)\<)KLYHU#) M6>O78'QM2IP$02"@=H&!^>T"]R!$(/(R?B^<>$T9@-OS!_MCK-W7.?%6^^]5&F6%.02B):8XQQ#MS%K!/'L:PJZE^)(_X/3?7BVJS"+\&R;G>;[ M!/DN01X)\G]*3#^5N!?S6279]%2"Z>(T653K4<5)WGC7@;VC\4W^AL_3_LQ, MQY5%9^W\R\;^MUH[\%*2*S]"O?]@JR&@=>'XQ9_-/&:SX?2P_""R?N/J#U!+ M P04 " V>49*+7U^?K(! #2 P &0 'AL+W=OV$ *S9#;;.D M?U_;L(1N><$SPSEG+AYG(YI7VP(X\J959W/:.MC/QGOL46EDAHZ*[$C!NJ?**F@%H-R+S@^P]S//25S\U_A LK#0R4^1XG*QB\I!^M0SRJ^%"W>IE-V M\1QG_2MMF\!G K\AL"E1K/RS<*+(#([$3+/O1;CB_8'[V90A&$<1__GBK8]> MBGV29.P2A&;,<<+P-69!,*^^I.!;*8[\/SK?IB>;%2:1GJRS\W1;(-T42*- M^D^+Z4V+6YC[FR1L-5,-IHG;9$F)0Q15=%O:!QSMYAT_;_DV81G:6G-'Y MFXWSKQ$=^%)V=WZ%6O_ %D=![8+YT=MF6K/)<=C/+X@MS[CX"U!+ P04 M" V>49*EOL$$K.;S1W30K8T3Z/O;/(4>Z=D"V=#;*^U,'].H'#(Z)9^.)YDW;C@8'G: MB1J>P?WLSL9;;%8II8;62FR)@2JC]]OC*0GX"/@E8;"+,PF57!!?@O&MS.@F M) 0*"A<4A-^N\ !*!2&?QNND2>>0@;@\?ZA_C;7[6B["P@.JW[)T348/E)10 MB5ZY)QP>8:KGEI*I^.]P!>7A(1,?HT!EXTJ*WCK4DXI/18NW<9=MW(?QYG8_ MT=8)?"+PF7"(<=@8*&;^13B1IP8'8L;>=R(\\?;(?6^*X(RMB'<^>>N]UWR[ MNTO9-0A-F-.(X4O,C&!>?0[!UT*<^']TOD[?K6:XB_3=,CI/U@6258$D"B3_ ME+C_5.(:YO I"%OT5(.IXS194F#?QDE>>.>!O>?Q3?["QVG_(4PM6TLNZ/S+ MQOY7B Y\*IL;/T*-_V"SH:!RX;CW9S..V6@X[*8?Q.9OG+\#4$L#!!0 ( M #9Y1DJ5+\1&M0$ -(# 9 >&PO=V]R:W-H965T&,"*S5#;+.G?US:$HI07 MVS,^Y\S%XWQ"\V([ $=>M>IM03OGAB-CMNI "WN# _3^ID&CA?.F:9D=#(@Z MDK1B/$D^,BUD3\L\^LZFS'%T2O9P-L2.6@OSYP0*IX(>Z)OC2;:="PY6YH-H MX0>XG\/9>(NM*K74T%N)/3'0%/3N<#QE 1\!SQ(FNSF34,D%\2487^N")B$A M4%"YH"#\=H5[4"H(^31^+YIT#1F(V_.;^F.LW==R$1;N4?V2M>L*>DM)#8T8 ME7O"Z0LL]7R@9"G^&UQ!>7C(Q,>H4-FXDFJT#O6BXE/1XG7>91_W:;Y)^4+; M)_"%P%?";8S#YD Q\P?A1)D;G(B9>S^(\,2'(_>]J8(SMB+>^>2M]U[+0_HY M9]<@M&!.,X9O,2N">?4U!-\+<>+_T?D^/=W-,(WT=!N=9_L"V:Y %@6RK4"6 MO"MQ#_.^2+;IJ0;3QFFRI,*QCY.\\:X#>Q&PO=V]R:W-H965TVRC@,;$M@"-O6G4VIZUS_8$Q6[:@A;W"'CI_4Z/1PGG3-,SV!D0525HQ MOMO=,"UD1XLL^DZFR'!P2G9P,L0.6@OSYP@*QYPF],/Q))O6!0JXIF8O_#A=0'AXR\3%*5#:NI!RL0SVK^%2T>)MVV<5]G&YNDYFV3> S M@2^$NQB'38%BYH_"B2(S.!(S];X7X8F3 _>]*8,SMB+>^>2M]UZ*).49NP2A M&7.<,'R-61#,JR\A^%:((_^/SK?I^\T,]Y&^7T?GZ;9 NBF01H'TGQ+WGTK< MPGP.PE8]U6":.$V6E#AT<9)7WF5@[WE\D[_P:=I_"-/(SI(S.O^RL?\UH@.? MRN[*CU#K/]AB**A=.-[ZLYG&;#(<]O,/8LLW+MX!4$L#!!0 ( #9Y1DJ' MAG1(MP$ -(# 9 >&PO=V]R:W-H965T[EG',_ MN*0#FA?; #CRIE5K,]HXUQT9LT4#6M@;[*#U-Q4:+9PW38J]4[*%LR&VUUJ8/R=0.&1T2S\<3[)N7'"P/.U$#<_@?G9G MXRTVJY120VLEML1 E='[[?&4!'P$_)(PV,69A$HNB"_!^%9F=!,2 @6%"PK" M;U=X *6"D$_C==*D<\A 7)X_U+_&VGTM%V'A =5O6;HFHW>4E%")7KDG'!YA MJN>6DJGX[W %Y>$A$Q^C0&7C2HK>.M23BD]%B[=QEVW\_@F?^'CM/\0II:M)1=T_F5C_RM$!SZ5 MS8T?H<9_L-E04+EP//BS&<=L-!QVTP]B\S?.WP%02P,$% @ -GE&2KX2 MMY?% 0 -P0 !D !X;"]W;W)K&UL=53;;MLP M#/T501]0.4J\98%MH&E1;, &!!VV/BLV?4%U\20Y[OY^DNQZ;JJ^6")U>'@H MBLY&I9]-"V#1B^#2Y+BUMC\08LH6!#,WJ@?I3FJE!;/.U TQO096A2#!"4V2 M3T2P3N(B"[Z3+C(U6-Y).&ED!B&8_GL$KL8<;_"KX[%K6NL=I,AZUL!/L+_Z MDW8665BJ3H TG9)(0YWCV\WAF'I\ /SN8#2K/?*5G)5Z]L:W*L>)%P0<2NL9 MF%LN< ><>R(GX\_,B9>4/G"]?V5_"+6[6L[,P)WB3UUEVQSO,:J@9@.WCVK\ M"G,]*49S\=_A MS!O1*7HU3IK6381VGDW0_A\4#Z!Q MEX!]R$.F1$'Y/;.LR+0:D9[NOF>^Q9L#=7=3>F>XBG#FQ!OGO12;W3XC%T\T M8XX3AJXQ"X(X]B4%C:4XTG?A-!Z^C2K&PO=V]R:W-H965T=8*HGQ6@J_@=<@#NX=^(T2L5-^**R-U:)B<59$?1]')D, MXS#N['936CPAF1*2.6$?=,@H%)P_4$N+3*L!Z?'L.^JO>'U(W-F4/AB.(NPY M\\9%+\4ZW6;DXHDFS''$)$O,C"".?99(8A+'Y$MZ$D_?1!UN0OKFD\,T3K"- M$FP#P?83P>ZJQ!CF-BZ21D72",'^2B2&^78E0A87)T WXAG991.>N MN$O"Q?^'CRWUD^J&28/.RKKG$RZY5LJ"L[*Z<5Y:U\7S@D-M_?36S?7XEL>% M5=W4IF3^5Q3_ %!+ P04 " V>49*/9?#5[8! #2 P &0 'AL+W=O MVFTLBUE4U6MU$JK M5&V?67MLHP#C EZG?U_ CN.F?@%FF'/FS##D(YIGVP$X\J*DM@7MG.M/C-FJ M \7M'?:@_4V#1G'G3=,RVQO@=00IR;(D.3+%A:9E'GT74^8X."DT7 RQ@U+< M_#F#Q+&@*7UU/(FV<\'!RKSG+7P']Z._&&^QA:46"K05J(F!IJ /Z>F\#_$Q MX*> T:[.)%1R17P.QI>ZH$D0!!(J%QBXWV[P"%(&(B_C]\Q)EY0!N#Z_LG^* MM?M:KMS"(\I?HG9=0>\IJ:'A@W1/.'Z&N9X#)7/Q7^$&TH<')3Y'A=+&E52# M=:AF%B]%\9=I%SKNXW1S.,ZP;4 V [(%LI\;ZK@C*V(=UZ\]=Y;F1Z3G-T"T1QSGF*R=0N?IOT;-ZW0EES1^9>-_6\0'7@IR9T?H&UL;5/M;ML@%'T5Q .4Q'&R*K(M-9VF5=JDJ-/6 MW\2^ME&!ZP*.N[; %!>:%EGTG4V18>^DT' VQ/9*3VG 1\ ? M 8-=G$FHY(+X'(R'*J>;D!!(*%U0X'Z[PCU(&81\&B^3)IU#!N+R_*;^+=;N M:[EP"_4E)!S7OI'G'X#E,]>TJFXG_ %:2'ATQ\C!*EC2LI>^M0 M32H^%<5?QUWHN _CS>$PT=8)R41(9L)MC,/&0#'SK]SQ(C,X$#/VON/AB;?' MQ/>F#,[8BGCGD[?>>RVVAUW&KD%HPIQ&3++$S CFU><0R5J(4_(?/5FG[U8S MW$7Z;AE]OU\72%<%TBB0?B@Q_53B&N9S$+;HJ0+3Q&FRI,1>QTE>>.>!O4OB MF[S#QVG_R4TCM"47=/YE8_]K1 <^E&PO=V]R:W-H M965T;,_XG#,7C]/>V!?7 'CRIJ1V&6V\;X^,N:(!Q=V- M:4'C366LXAY-6S/76N!E)"G)DM5JSQ07FN9I])UMGIK.2Z'A;(GKE.+VSPFD MZ3.ZIN^.1U$W/CA8GK:\AE_@?[=GBQ:;5$JA0#MA-+%09?1N?3QM SX"G@3T M;G8FH9*+,2_!^%YF=!42 @F%#PHPH&8O_ 5>0" ^98(S"2!=74G3.&S6J M8"J*OPV[T''OAYO]EY&V3$A&0C(1#C$.&P+%S+]RS_/4FI[8H?+&6XB M?3./OMLM"VP7!;918/M/B;>?2ES"'#X%8;.>*K!UG"9'"M/I.,DS[S2P=TE\ MDP_X,.T_N:V%=N1B/+YL[']EC =,976#(]3@!YL,"94/QUL\VV',!L.;=OQ! M;/K&^5]02P,$% @ -GE&2K#?,DZS 0 T@, !D !X;"]W;W)K&UL;5-M;YLP$/XKEG] 34C2;A$@-9VJ3=JDJ-.ZSPX< M8-7V4=N$[M_/-H2AC"_X[GB>YUY\S@8T;[8%<.1#26USVCK7'1BS90N*VSOL M0/L_-1K%G7=-PVQG@%>1I"1+D^2>*2XT+;(8.YDBP]Y)H>%DB.V5XN;/$20. M.=W0:^!%-*T+ 59D'6_@)[A?W]P >GAH1*?HT1IXY>4O76H)A5? MBN(?XRET/(=)_TI;)Z03(;TAL#%1K/P+=[S(# [$C+/O>+CBS2'ULRE#,(XB M_O/%6Q^]%)O[SQF[!*$)QTU>1.>%?4SCG?R#C]O^ M@YM&:$O.Z/S-QOG7B Y\*J@$ )$# 9 >&PO=V]R:W-H965T7*H5(&5358G42JM4;9^],( 57XAM MEO3O.S:$TI07/#,^9^;,,,Y'ZUY\!Q#(FU;&%[0+H3\PYJL.M/!7M@>#-XUU M6@1T7LTM,-&..$X:O,0N"8?:E!-\J<>3_T?DV?;^I<)_HU_\HW']0 MN(6Y_E"$K4:BP;5I&3RI[(JZBR[[=\S32O_!I6;\)UTKCR=D&_#%I?(VU M 5#*[@HWH,/WL3@*FA#-.[3=M"63$VP_/P"VO,+R#U!+ P04 " V>49* MGAG\Q^(" .#0 &0 'AL+W=O-O1^KV]]2%P_,/]B^->67FE=5\ M([(_Z5Z>5F[B.GM^8.=,OHCK5]X9BERG<_^=7WBFX%J)NL=.9'7S[^S.M11Y MQZ*DY.R]/:9%<[QV_!]EN(!V!;0O(+.;!6%7$$X*_%998_4SDVR]K,35J=K1 M*IF>%.0I5 ]SISN;9]=<4VYKU7M9DSA:^A=-U&&>6PP=8.@8L3$18=!#?"6@ M5T&A"MK4ST8JYA,5+29N,$6K@GC)1 @ !0/02$H(I82&E$4\4=)"DMM* ,BJ M9 :5S,!#B3%!! FB^U8B0V7L33 ;$T.(%V$A+[3F)3Y6< <:#5)@S#>$LLTW@O.$@$!)+$-+< X0,PB (7.5F^L'@.Q^ , M(" $DIF% J< ,1&ULE9CKCILP$(5?!?$ @.T0DE42J4M5 MM5(KK5JU_-"#Z.IG^62[X9'U_FK,WJHNJ7YBBE]M[* MHFK6_E'KTT,8-MNC++,F4"=9F5_VJBXS;1[K0]B<:IGMNJ"R"'D4S<,RRRM_ ML^K>/=6;E3KK(J_D4^TUY[+,ZK^/LE"7M<_\]Q??\\-1MR_"S>J4'>0/J7^> MGFKS%%ZS[/)25DVN*J^6^[7_@3VD(FX#.N)7+B_-Z-YKN_*LU$O[\&6W]J-6 MD2SD5K=>T/OO\I761B\56+:V*JBZ?YZVW.C53ED,5+*[*V_ MYE5WO0SYW\-P !\"^#6 S>X&B"% 3 +"7EG7U8^9SC:K6EV\NI^M4]8N"O8@ MS&!NVY?=V'6_F=XVYNWKABT6J_"U330PCSW#1PR_)5*;$-$5"8V JPH.5? N M?G:C8CE1T3-)QU2]"A9,I*8 BH($2Q%0BK"E+*.)%)N)IR/2(XN1D"A@6,<, MZI@!'6RBPV8L'7>1&QDQE!$#&9,V'F.KKV!F !2-H!LIQ>YD;&$,I:$)68SEHR[R(T,%F$/ MB@B+;(#NSPR G%/#'(;(@)B9(P5V,T:QLP$:2UT&LVE_;(@'2X<8[&>,8F@ MLJ:9_8>E,>QIC&)J +*UT&V-85]C%&-CMFF!.>JA> 0Y7(EA7V/(V%R+%CL; M(UA;.D!CH:XQP[;%"+Z5 L@Y-=B6&,&74@"YFN'8=3C!==(!(HP9QW;"D9W, M'2D5Z]AM ML/N15XSTK;8[XW4%\KY26)F$4F(1'F>VN M#X749*O_#)G_8! M "R!0 &0 'AL+W=OJXF@.QP*[7;U] UU@E]T:8X3\SOP$A&[AX MDPV \MX9[62.&J7Z \:R;( 1N>,]='JEYH(1I4UQQ;(70"H;Q"@.?3_%C+0= M*C+K.XLBXS=%VP[.PI,WQHCX>P3*AQP%Z.%X::^-,@Y<9#VYPD]0O_JST!:> MLU0M@TZVO/,$U#GZ%!Q.J=%;P6L+@US,/=/)A?,W8WRKVL^,PY7^$N0/"*2"< X+X MPX!H"HA6 7@DLZU^)HH4F>"#)\;#ZHGY)X)#I#>S-$Z[=W9-=RNU]UX$S\\9 MOIM$D^8X:L*%)OQ?<=HJ(G^68 TP4X1.BM#&Q\L*OK^B[J^FLQM\E*PZ7 M)G"#1$Z0R $2K$!&S=.'("Y-Z@:)G2"Q V2UZ\=X4R1>%!E!MIIP%[I!$B=( MX@")5B!;3;+^0Q+'ANS='*F3(W5PQ"N.='/\R69#MIIH_"E;Z(]KK4G"O0^?31(Z_1#^AL4*B5F>[U7(S/R&@HWD\O))Z?Z>(?4$L# M!!0 ( #9Y1DH \1@@]0$ $<% 9 >&PO=V]R:W-H965T&R6]R/U6RF&+D"A;H%BLV "]>E,S3K%4 M)F^0&#C@RI H05$0I(CBKO>+S/B.O,C869*NAR/WQ)E2S/_N@+ Q]T/_ZGCI MFE9J!RJR 3?P ^3/X /XU<$H%G=/5W)B M[%4;7ZO<#W1"0*"46@&KXP)[($0+J33^6$U_#JF)R_M5_;.I7=5RP@+VC/SN M*MGF_I/O55#C,Y$O;/P"MIZU[]GBO\$%B(+K3%2,DA%AGEYY%I)1JZ)2H?AM M.KO>G*/5O]+C5APL" >@MR!UD[ M@ZP?@X3_$4B= JE#(+QK]H39+)-SB4DU[&8D:\8DJ%2"E6I*J[;:;!"HI;YNU)U/ M__9D2#;8M87FW5G\ U!+ P04 " V>49**TMB;N0! #%! &0 'AL M+W=OS$X@:010=KL:M5* MK11MU?;9@>&BM3&UG;#]^_I"*&7=E]@SG#GGC.-Q/G+Q*EL %;PQVLMCV"HU M'!"290N,R(@/T.LO-1>,*!V*!LE! *EL$:,(QW&&&.GZL,AM[BR*G%\5[7HX MBT!>&2/B]PDH'X]A$MX3+UW3*I- 13Z0!KZ!^CZ GYT,,K%/C"=7#A_-<'GZAC&QA!0*)5A('JYP2-0:HBTC5\39SA+ MFL+E_L[^;'O7O5R(A$=.?W:5:H_A/@PJJ,F5JA<^?H*IGS0,IN:_P VHAALG M6J/D5-K?H+Q*Q=G$HJTP\N;6KK?K./'?R_P%>"K LSZ8T27L4]ILV+W7V5N $Y^AFB";,R6'P I/,"*399PGLDSCA M=^4XV?@)-EZ/&TNP_8=@N_+H,#N+Z9W'??0?FUNORM:CDJY4'&:_4/D01]BO MDGI54H]*ME))WZG$T4>_2.85R3PBNY5(YCNP_4H%+:X1 ]'8 9)!R:^]'=Y% M=I[1!VROX5^X&_"O1#1=+X,+5_HRVRM7XDCW7&KWY0YH% KL]WIO7"3 MY0+%A^G10//+5?P!4$L#!!0 ( #9Y1DJ>8(A$U0( &8+ 9 >&PO M=V]R:W-H965T41"H)TR9M M4K5IV[.;. DJ8 9.TOW[V8:FQ+YI>0G8.??Z'MM1[N+"V^?NR)AP7JJR[I;N M48AF[GG=]L@JVLUXPVKYS9ZW%15RV!Z\KFD9W>F@JO0"WX^\BA:UNUKHN<=V MM> G418U>VR=[E15M/V7L9)?EBYR7R=^%(>C4!/>:M'0 _O)Q*_FL94C[YIE M5U2L[@I>.RW;+]T'-,^1KP(T\;M@EV[T[BB5)\Z?U>#K;NGZJB)6LJU0*:A\ MG-F:E:7*).OX.R1UKVNJP/'[:_;/6E[*/-&.K7GYI]B)X])-7&?']O14BA_\ M\H4-0L1U!OMO[,Q*B:M*Y!I;7G;ZT]F>.L&K(8LLI:(O_;.H]?,RY'\-@P." M(2"X!LBUWPL(AX#P+0"_&X"' #QU!3($$&,%KW?7F[FA@JX6+;\X;7\?&JJN M'9H3>5Q;-:E/1W\G][.3L^=5@)*%=U:)!B;KF6#$Q.@6V=C(&^') JY5!% 5 M66"%![<+K&TB-I#-ATGR=Y/#R*3U)CKWHDUDBMD4_IS-BM-0!% M,V+H !"R4N40%<[N6&'0"EM6 3*U>H:,E@F3"/LXB0TU$ RC%$>&WM2,.9S1 M)R/P1I* DL26#'Q#DDR5!$%(@!0V[DX.4B&&Q6)0+ ;$C!]W%D\2 RE+#*0L,9"Z)Y: 8@D@%AIBB74W M2(0)P0:WMCDF M\"%0/88QGZ'Y&@'S&]5$ZI[D+7W?@7ZG[:&H.^>)"]G9Z/YCS[E@LGI_)F_< M43:]UT')]D*]QO*][3N_?B!X,W2UWK6U7OT'4$L#!!0 ( #9Y1DJRJ.*9 M ( %0& 9 >&PO=V]R:W-H965T;?QP\ M20R%(T]M2\7?)V!\R%S?O6R\-,=:F0V2IST]PD]0 MO_J]T"LR4\JFA4XVO',$5)G[Z&]WO@VPBM<&!GDU=TPI!\[?S.);F;F><00, M"F405 ]GV %CAJ1]_)F@[IS3!%[/+_0OMGA=S(%*V''VNRE5G;EKURFAHB>F M7OCP%::"8M>9JO\.9V!:;ISH' 5GTGX[Q4DJWDX4;:6E[^/8='8<)OXE# \( MIH!@#O"C_P:$4T"X"""C,UOJ,U4T3P4?'#'^6CTU+X6_#?5A%F;3GIU]IJN5 M>O><8?O?KWC29HG@3)X^. %0I8 M(8!@8133A'B2-9IDC0 B'+!! 9M/N,0T,9[$G#EV43P$D=Q!W+EK_B>N=*>P][GB7($&>@_Z5:IUBY\7#"IEIBL]%V.?&Q>* M]U,/)_,?2?X/4$L#!!0 ( #9Y1DK@PF-#A0( 8) 9 >&PO=V]R M:W-H965T%W4D%(K8^VZ@S!7CBUC1MXWLQM0=W9>29L&YQGZ$2;NH,; M;)%3VP+\MX -NBQMW[X:7NMC1;G!S;,>'.%/2-_Z#68[=V39URWL2(TZ"\/# MTG[Q%^N4XP7@5PTO9+*VN)(M0N]\\VV_M#V>$&S@CG(&P!YG6,*FX40LC3\# MISV&Y([3]97]B]#.M&P!@25J?M=[6BWMN6WMX0&<&OJ*+E_AH">VK4'\=WB& M#8/S3%B,'6J(^+5V)T)1.["P5%KP(9]U)YZ7@?_J9G8(!H=@=&"Q'SF$@T-X M.D2#0_39"/'@$"L17*E=%',%*,@SC"X6ENW0 ]YU_B)FQ[7C1G$ZXAVK M)V'6 MDJP?DMRE&1J+%0K_:.H?*;62D$1 .ED()U:TF#")(L:$F2ER=$SH1&8]D5%/ MI.M1GB=6S^03-^B'-G9K8J";6U2@5*V(MC=!1NKW4,?KI MF'A218X)\Y_3F1GUS#0]09B:"1(C0?*\71.#6+5=)2:>8I1RF%C49M4QP:2L M=VKF1C5SO1R19R9(C03I\W+H$+63RU3[TWE:>SRG63^FD6K\A?@H)BJQ M=NC44?Z)FEC'H?T2\"&@V M_4?H&^XH->3F3;_3RAO #X&/=$6N+*!L]8D < M$**0I>XYK!4J=BD9-PT\4+Y,V!K+T2PW%/7#K<,=KS[Y/U!+ P04 " V M>49*I"0:/U8" #E!P &0 'AL+W=OV.FS 0?!7$ YSYIA<1I$M(U$JM=+JJ[6^'. &=P=1VPO7M:QN'$,<*]P?; MR\SLC@W>K"?TG54(<>>CP2U;NA7GW0( 5E:H@>R)=*@5;PZ$-I"+)3T"UE$$ M]XK48!!X7@(:6+=NGJG8*\TS=;!(_J)^*_NE8H5&%7V=8-:5I/6H>BP=%_\Q3:5> 7X7:.>3>:.=+(CY%TN MONV7KB<+0AB57"I ,9S1&F$LA409?[6F.Z:4Q.G\HKY5WH67'61H3?"?>L^K MI?O%=?;H $^8OY'^*])^8M?1YK^C,\("+BL1.4J"F7HZY8EQTF@544H#/X:Q M;M78:_T+S4X(-"$8"2+W(T*H">&5$#TD1)H0?39#K GQ9S,DFI 8!#!LEMK] M G*89Y3T#AV^GP[*S]1?).)\2QE4QZG>B0-@(GK.@\C/P%D*:ID0A,KIP&T:-J&,PIR:GE\F>91,>>]!+(*\N(K_S%VK?$ M"W^Q&5K.57YH@#\@/=8M&PO M/?5#^#W M4N:L2*)_%.(B+9+\AQ?#XU9X%.Y$")?QB^'_?[IRR6/DA=OOI?1F^_S-Y=I6"Q%DK-1,F7O MDCS*U^PZ42M$:<(.F5SP3,CO7^9OOG^)<]2\4_8Q3?*%A#E3,:W?O11ACQT- M C;L#T[K-Z_$I,?ZIW3SK#'3P.,"\>N'*!'L.A=+^9_U"1KF6S&/9)YQF/F) M+T5]U.@^ROA<).QN(3*^$D4>A3* 3<)>RX(7 $3&8Q@R%8_L)[&NC[O+^#1* MYFR\7D[2N'Z7PX;U[RZ*+$/4KB(9PLI_$SQ#\K%+GC< /CSLGQX>]5N NXIB MD;$+F#=/LP9DHS 4 C4DFV>M3#)B_F]_^(-/T.TR+L.O MX,L&G>HC];[>L3\/&_R&J5,U/>;S^MT9CV4#\HL4Q#J10'6XDFD<34E:WO*8 M)Z$ ^H*]D&S?2(B&YTO"BVD$ P_ +GP97[+]O0.VQX#R'Z,X!DUM /N7(@$* M]?V&P*S.I83=7C=N<[E@P%T6XH7X1Q'=\QC&-S89+T!\#W.1+0&4>R'SI6\4 M: 4:4,DR$0I8:A*+@"4B9^F,\3A.'Q#S^J2;3*QX-"4PTAQL!PLK0#>,0IH# M^S:/^90FA^%FU&\R,.49B#WNBYBO$"4"U[^C?R=#X#CBDRB.\D@TM[)D6?$U MTL1S/RM -,3C"@5F$_&3-!=MRWS0(*R!_#')6IXR"?Q$\L^*O,@$R](UCQ'( MP%*0#%.:;":S@]XF6F^BPH1L/*Q!9PG(M=MT<\D;K$%S &_ZQ**3!O( M@U8U4NJB- U\.AA3D83-P1ASO)8K'HH?7D!0(45V+UZ\80UY0 N]2.,IN(,_ M__'5<'#V'4EPOO9(N9@)0&#*I#+K>_W>H _$SQAH>B%>LY.@W^_C_]JT,U[D M(&_1[V(*-$C-MQ%Z#JVDI4OP(0LNI&VOH=K)O]MW[.A5<'K<#XY?G6W>E?&< M@5\0RPEPSX1 - ALH6BUA:,I&%9@(? +#D;W DP@_-NGQG;65,RB,&JQ)+*5?UNEB[#L/O^K?=#^#<<["P'!'#@Y M=$I[[&5+P-H0-LMZ"AVF:1SS#*P@T),6:$01C04:0K(I!FF;K85HAYEIM^"G M*O5/1;HZ^TD8>Z=N1]<[K3.N7HG"J%8H(PA J[_QJVW+9IHX0&;M[YO0@N7G M6:@BLRFL$J<4G-3'O1>)P/P)A_'I,DHH/0 MH1Z ZY-R0\B3UD%M^G0IV2Q+EV:HAYW*R>[K%0ZT\6P@;7D0)>"+(<(T>S(0 MU?@IWK^^\K59T&^V-:I>*+WX3@2DS8+E_+&Y$T[".VT$^P1!!1*]_OU;+J-0 M\3N*"T0PT2-+R]'1GC27>@#>+^#BD-\+3-&_L=;I]R*'/0!H'K'LP3((=L7 M_WQQS49YGD63(L< %B51.^MD&QL;KD0K%Q8"=G03GH%22'.SD+FCVCV:X=PB Q!$O8DI!-_U[H M%!;9!]EJ"N$X\-(J'7R+UV20"D0 0.BT=+L9V\%R=?%+7=>Z4(:_B@>EM&0K M.N6O95KOB_THBSX)TS+!-"-49;5L8GQ'\ M1@<\S(HG:_897.5])!Y\ \D\7"DB@%,IS5EC,">=K$;$O]Z)QYR]C<&%-3S% MX* ! -M05P\ D+D@)7N(.$81.X!W9DL)C*:1CS#U'$?<\5A_SNS M(/US\%W THRB6WU; Z#O0B0$U&.3*%V!=UCRD/;'RI"& 5J3"-P(+DAR@U*#P)"@\$L$3/',0%0[09C" ZY0OX]P)"%K!-RXBL M74D 4'@UBJS%#"&\60BQ7S!9/BGN)M6#-W%M IN$3@(>U+ M?N>HOM,B1+6!Z J=GE283 3P418A.$\Y*Y!/FD*ZR %$78H,I8I2/R +3D8C MH$PIA'YS^/"R EE<@+_%8@7$B)-4"5P Y M5')U5UE?G/GR>">V+28005J6%1Y!;C.Q!S+'RDR?X46#&"#4)DAD1H4"0AAEX[3 M5*B]M,.(UXIH> ^]' C]DF>_"1*>"C)8Q['NB[B;48Q.&(#\KL"E1Q2KH4RY M>RZY^M\5B!5$-R22JE174(BG;)X@%2MS'46S_>@ /%6D;#2:GL!C@)*I:_@# MF 2S@"JA$%-MM.T:@-P*[ SLCA1T'?OZ< *I(8[17)6*$I;A]Q@<^--'QK,, M8X 2 (! KZ[*1SCC)3(,/34N/!63O#3WDDS%?G1_H*31\0/.RE7MLLIA$K@: M766QPLIJG:[ -"MO ?H09%H":)$+#5BQ ME=\H3/<7N*"'W38 (CR(L M""R]?=6%)BDBQHHJO%I&XQZ5!-2*2FM ?2",S M$!NDIP0J( MQ13U(?C 68FAGUC9S*IJCF;HQ\&"!TU%MBOJB<0_Q;P=S:$6.D5[[21]FZ)3 M8',JQ8"I=EV08:H1-J3\1%")P%(7_1$.G$6YH8.'UMYP90CA"B;[%)K>H-8G M>4N2YQE$T(P=:'4@CD)Q ZD:'D]LC%7VAP>DZ< P10Z<69@$#G'0N5_HYGXS M&S;),@LL?>,*TXA,A9FX<#8E@2(SRTL 5Z":8;0"GZ ICU14DJ/F(I>^))'- M-@G]$3 ;<+6!T)?>N,?>CT8W-M9!):'$+5HZD$9.GP12S3K**)%Y5IAX!6)" M&,8&??RO/W@2!0"=N)B6L#M!&%G/49(4,$.U$:"0F*W&B#)%.H,CE80K^ULR MPN"S SC*HI@$K1;VD!V)K:%IC3LQ@(H5%(.,9V,+KA'T$Z& @1)PVQ^$SM%\6 MD<%)"3906:'UJD=XP0*C8E[(7*]A80<"K="2E)Y7X,$$FJF'A4H;W8;#2KJ'.3.18RFDZF"%GP%R\$ ("E*=53*$5K:7.<. M*$JJ_P7O9-0# S9V35^J4H,RYQ1C6^/N50A.5,*#E1[2>TJHRE2Y=FZ:0Z0! M%2Q8$2*.X!LD$DNK=8Z"/;?GP#H \-/D;@%LF1>1LH!P+2C-05^M@FJR")EM M+!+Z;-0K.*=!7?P!B[]P6");Z_M;90UF7(E)YDS)'T0,X-1GO@K<])>(8 MD:IIP,@PAF@!] KIB7K7CN>JF("J.3F.@[S*Y66@HVMEY_279*6)[*D4C0F3 M+8IV&E35ZA1/21Y*,$$$%^D# TG'PK$)/B'&7)EC?JKBJ *+$I^513E>DK[^-J!!@7E1XR#((S M<89>EZFZ.FHX.V(C- M<*(Z)(9 /$/=4(4("H(@203S%,D%U3PX!I"0GN'*+K,!_R5_!(/RN_+3A:1* M4SK!MA$R;U&R*C#]>" C;V-MI2YX7%B?6R2-V3@9,BTB J4B%G(E#EY,ID*& M630A@-$GHY?Z@$D/&["?BQ3Y 1$J> M7FS(/C? 3;5; []E=E2?1Q /-K&SCD+GH:KB"MOD,64(2:H!,Z7.M583,\T) M#W2ZXE!$1TPM2!#Y4FR+HR25P)*:!#K +*767ZI7@#P@>Q6+T+KD%1 PGP#+ M5&3$/DHG_/TSE9 E8'?,$X;ZJ]A._.Z8-9!FS2;TDA'8+LWZ&\OZ:OI!8O!1 MBX$Z-78'X G54I\"J4C]VHK)2%''$8=KQ=\*S_5W#NJ,L&6G3!T"[VN1.3!7 M0WL%:GM1K^GL0=38.X./,_I[U.O#7Z+5\#OF[Y@LM? 0,#BDA'PPZ WLM,H_ M%%1[;#CHO;+;#(YA1+G/UQ&U2D:'?A7"54FOB:VIJ3]O9.[%^#X$XD M/>\=(7/Z#"\:Y.P3.0=J'QQ1[M$ 2N?B:+# $D0QG>8LTT2LC66@DD:O#3HS M'YTZ1 M$>)V/3@557[!6E:U253Y 3=4-B)2>WF6DUVOG#AD!NHE5_'!=F515 M0 ]I<#+IZU*=3N&",<8"9#./3D_\=FF!A2%R%0E I,K3V$.B35(JS9E?:7M, M9I;2*9##+T)^BP&JR=R7X)]5KT/Z M'Z\O+%<2.O0Y[QW#G4/ZO"AKSRN.O1BH_'@3/R_\? :Y/J,Q^%E3;;4K_:,+ MXC5MVQWG-E53=RZQ_.L('N!"NYB./^Q4+J@W"R"^6@;Y1<4#?;5+=@YAE MVQ!O4(J29]K$4.U!3D9LLG8&54_7HF1"2Q.!$"\.8QUP? M64Y$ OD/$ SO]GNGK*T;KP3S&$8->T.-6;UW 3C7MPK?N%FV2;AAW1X[@34Q MI#AM='^3/)S JB[I;LN&D+%N"+E2AP:W;0TAEZ;G53=-.MS>@WWX XND&1[*Z,:<;*IK+%CFT%5Z+0^V*S"H M)$:1U D34P3!YHFE*O%@UDAL6*)2--IFUF7&#O,FHCS:5.=$N, '?7PP,B<% MJAQ\R:,H7$1 _>2W=6ISZ7(]"M3U(<4*HWD[QH\3 0*,JJ("%I[[ST 62IWJ.N+J TG=76 M>+"$J)#B4;VDSLF+1#,24T#U1$5C75VN0P W 8=5B3G5)S5_ITX]PHY&1U(] MD202J"(%!KUX<(#N4E%-51[P++LF$($I:*I15+J315BK\UGL*O$;2(_>,&B!) M#)UDCV>6Z\ZS-9$69/<85VNJY9:W@1H#0;L.0]AB@Z[61ITMIQ!8X:RZ2,3< M'FA0/R]$F-1$4;Q=OJ8(6RBF1LJFH=5)7S'2>\9H[_T9;]B0\H MU=P3Q%NOP ^U-OQ1;YVQ$_MH)P_8IE;#,(4<#PG2A^AI)P";)IM@?.7W1]C! MBWUBU"!]@TDF"D_C05/376M'[.!I3A%ULU79'-VI@]J6V+"<3(/LB8(=;4QW MHVNZ["@*]0,4S39J1W+X:A6#@4'Y4]:FAX=V&Z +[+K4WNPFH?MFJUEU#!Y) MT [V_%\\8EJBRGEJC-LI55 :1JTZ,L\BLG1J5 $&"EM_\?CM49]%4A\ 55)Y M'&)G#QV DB)%F3HCQ("*/9CC&3P_.B0$P08WNZSLPGAL6!FK"*#[E?D#G8OA MX9%NOJPAG=@:2B@EOKML?USL ET<0K!Z '[I4,CO_,0'5X> MG0;GQZ<0VVE":ZH 3@T1L(^669'!9%4_!TX]?G3D1XICD1=&I4LE\T.@]-.C MDWMDSXX5GA",G\'59;L*^X9_LIJY5:JJPNVR^02@/@E.CH_8,0 ]"$Y.3MD8 MK/]7,W%@N3@X(L.]"QO[P0E<_F^R44%0LE$](F#.H..SPV#CHX[\+,V M_-OS# =]O^\ZHUS*-'[I1\4@X:TTU2%5(=S-,X@@\)1KY'2\-1][<& MPN5/,;XZQ#35O!__5+8.)VQP?MYG9W\RR>"@;R^K'W04B*?%%3AY+%/;6R4; M49%U4":,N4[PI2!FS;(W!A;NVX3TV(*@CB6&_>%QKYZ\8M:J1WG\!?9+++$< MK,_/?A-KDKTT$9Y.&: M;'CZRS%'^""6,](6E+"N+(/*BCKLN1Q-)4M2@ZB=\'L29D:4)7(>FSYA66+-?]><& M]CPW;CXW;CXW;FYMW&SMI!XYQ;7N6O?!^3+M0+30?71M.Q1O&U:])2/^956V>!,6MX5]MQC]]QC]Z_> M8U=7#:>Q"3N85 /3 6K%M0/"KAKQW$CVW$CV3VTD^[H&KE;G,@X7$$ZJ2I6G MAVMG_7ANGNK0/-7*E7H758#/#SBE^*!:\]^-1<_=!EVZ#3II3K,%(7!:!\PY MU:Z,>C[V?3[V?3[V_7]R[-O)WHS%G/Q=^0, SJ\ND+,P(_XG;<[SX>&_WN'A MTZL.E]BD&4L2$1#&YEE2)4FC4&;L/!ID7T=WXWT%VH"MP1P\&2JP,704OE;G M[V6^9L#M_"I'"SYES#7P\=5L*EC>5%BYUD^\FD<_V][(V3YGN,.Q6 M1GFZ6JJ:P):B36.:<]_4$=HUJO'F3"HQJ)(:Y&)88FB53)OE$XDZ%+%1(KJ7%2IVNF,EXJFB MTJ@3-'2C62KH^O+SUG?!^@L'_K=\=ZL@?+NB0=UC=R7D8.,K\$>KK/W-SS^" MUN6+"VX!6>/KJ?-$9))=7U^#I>G=]%QK9$:Y?8IM,M>L=IB7;3A4[7G*ZZQ-U>>;@-XH #VE\*->V^OTZ_]8]NLWBSN^RI'7TIG?.4%> M8D\2@+F1KUT2_ WOV7]ZKKYAL=:Z2[GO\KWK>\PHI:4RB6>@6I1/P>Y]Y?H#BO4BS><15TQU*NVE9 ML?[X"NST5//E_?C+[=7!AA"II0$^,/UP'_'M0\72])(V@T>G S!@[PK\L3:P M;WS%DX!^1U-'+>@[,C>J H?V?OQ3^P\]6**NS:\/8DL6*&M]Y%FOW_]3@W<% M-F9"J( ^ZH']A\#NMVG QJ#B"S::HL63Z:\.1 TU1SVM#7!9V-H?.F1NGM MD=O=(BTDH.0)%N][MJ6Y(3]QG(;J-S#:=G[G_^&8=\M5G*X%)CC9?42_W>5? M(&!W_)&]5=&U,JG?>'V-A':UM^7IC_[Y,-TRKG]SA>Z,Z E?7Q,R5?#T[\7< MQ(ZL>[VCCV!NP(;EU&:G.ANAHPF<^K)VM2/[*UOE;B^ES-_\-U!+ P04 M" V>49*61![BT<" !9"P #0 'AL+W-T>6QEHJ-S M=/[GIXLCA95>,[@O #1J.!-5A NMRP^>5R4%<%*=R1*$B612<:)-5^5>52H@ M:663./.FOC_W.*$"QZ&H^0W7%4ID+72$+P87Z7 JI&IKNPKN=]D-WPGT/0M(&1L I]@YXK D6H,2-Z;3 M#FZ=3T*HLQ?KTA#FBJR#Z0R/"6UCBBRE2D$-90+C:H MM>3&2"G)I2 M0Y_1&48V <;N[=?P+=O2;C+DQM@M\3&R%+UI9MV9XZ[Y+?*F MFM/>E#U,%Y5T)?6GVDQ'M'U[<.!.04:;MM]D X!1)V7)UA\9S04'-YG?%@P. M+!B'I*^#"JGHH]&S1R4Q#E 8K4!IFFQZ?BA2+J#1_7%JLD.9IT?(_*_7.0JOC2BO7J/ ')V#)#S8X!\Z<_&ZV[& MC>MWZ_(=O&A94Z:IZ' +FJ;@>.SK)\*W]LG%MJ[ \0XV\IHLS3MW2]_DII"1 MFND[.\4V&.'1_F+!@_DP:C%(1'BTOT)*:_Z^+3@^IN.?4$L#!!0 ( #9Y M1DH)4J'3T@( %D4 / >&PO=V]R:V)O;VLN>&ULQ9A=3]LP%(;_BI6K M71E;R/ M[:M/YS]6SGVP7[6Q89%M8MQ>YGDH-ZJ6X:O;*@MWUL[7,L*I?\_#UBM9A8U2 ML3:Y&(VF>2VUS:ZOCGTM?7Y]U3;>M/H,?ZZWITR64>_4JUPMLE$&=3DJ[#H] M'@]$E_Y_F-QZK4OUS95-K6P\0'EE9-3.AHW>AHQ96:M%=BQA-[9BWVW4<<_N M[:$KJ,U8]^K[:I%Q:$<9X9F=#GIE5,;\I88;_K[B+?APD'?.5LH&53%H!6=T M!1P5NY5&VE(Q!"D(2'%*R )!%@1D<1+(EQ8''D608P)R?$K("8*<$)"34T). M$>24@)P."_GHHF*C,";)< 3@'FK@_@W_=8$S*-GQ@W728 M<\#L!N]\)0]Y64.7 :HQ)N4;/K!P7O2[U5 KVWE06;H&YD'VG2TAU4OX1#$F M91P^L'+(*.)8.9QR#D\AG;XPXC.,2;F'IY!/7QCQ.<:D],-3^.??8<2^O$J, M20F(IS!07R")$9ZB4P82*0S4]PL)CC$I XD4!NK%%!B37/&DL% O)E[R",I" M(H6%^@))C#$F92$QL(7(0!)XV2,H"XD4%NK%Q!82E(5$"@OUY":LAS F92&1 MPD*]N8DM)"@+B106ZL6\P)B4A40*"_7--PMLH8*R4''8B#ONOE5JK:VJ'N$5 M :Z7TI1+S]K#81TPGK3J73?&W,&U)_O@9+=?UO9QW.J[_@U02P,$% @ M-GE&2E6@+.EL 0 'Q, !H !X;"]?4F@6["VTT"WH37FP6]&:\W"WKS/WQK2Q_; M>+U9T)OQ>K.@-^/U9D%OQNO-@MZ,UYL%O1FO-PMZ,UYO%O1FO-Z)H'>"USN9 MZ.U*;4W^[FW5%F[NDKOA3VLF<#M_J\W\&>/4I_LG2OMABU'CSB( 0 U!, !, !;0V]N=&5N=%]4 M>7!E&ULS9C=;L(@%(!?Q?1VL0AN[B?JS;;;S61[ 0:GEDB! #I]^U'4 M)3-=HE&3&AM Y,BE36-SRF MKI\3Q\6"SX&PP6!$A#413.S'-DJ_KE"6DL4F1HJ$@1U0X7-CVT[KW%7BO))R$9JM* M"9!6+)NTI S. Y>A!HB-+D/-/3FO%._' =#PC%$PG&+A.,."<<("<<]$HX')!R/ M2#CH L(%J-2+$JE6)Q*L4B58K$JQ:)5BL6K%(M8*1:S,BQF95C,RK"8E6$Q M*\-B5H;%K R+61D6LS(L9F58S#J\HEES6S949*'R// \ 3 @ "P @ $ 7W)E M;',O+G)E;'-02P$"% ,4 " V>49*9O,+8(( "Q $ M @ 'I 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( #9Y1DK ME2J M\ "L" 1 " 9D! !D;V-0&UL4$L! A0#% @ -GE&2J6DL!N' @ 10D M !@ ( !^0@ 'AL+W=O49* ?@1]"D" M !E!P & @ &5#P >&PO=V]R:W-H965T&UL4$L! A0#% @ -GE&2JZY"+3A P N!( !@ ( ! M]!$ 'AL+W=O49*[NE\E44# #2#0 & M @ &N& >&PO=V]R:W-H965T&UL4$L! A0#% @ M-GE&2G,4?"VU 0 T@, !@ ( !*1P 'AL+W=O49*EOL$$K&PO=V]R:W-H965T&UL4$L! A0#% @ -GE&2CGLT\JU 0 T@, !D M ( !KB< 'AL+W=O49*AX9T2+&PO=V]R:W-H965T M7Q0$ #<$ 9 M " 8@K !X;"]W;W)K&UL4$L! A0# M% @ -GE&2E+*RFC% 0 -P0 !D ( !A"T 'AL+W=O M49*/9?#5[8! #2 M P &0 @ & +P >&PO=V]R:W-H965T&UL4$L! A0#% @ -GE&2CY= M6W>W 0 T@, !D ( !6C, 'AL+W=O49*L-\R3K,! #2 P &0 M @ %(-0 >&PO=V]R:W-H965TJ@$ )$# 9 " 3(W !X;"]W;W)K&UL4$L! A0#% @ -GE&2IX9_,?B @ #@T !D M ( !$SD 'AL+W=O49*M<&9 E@# -$@ &0 @ $L/ >&PO M=V]R:W-H965T&UL4$L! A0#% @ -GE&2@#Q&"#U 0 1P4 !D ( ! MZ$$ 'AL+W=O49* M*TMB;N0! #%! &0 @ $41 >&PO=V]R:W-H965T8(A$U0( &8+ 9 M " 2]& !X;"]W;W)K&UL4$L! A0#% M @ -GE&2K*HXID @ 5 8 !D ( !.TD 'AL+W=O&UL4$L! A0#% @ -GE&2OA"OF^1 M&0 $W@ !0 ( !NU 'AL+W-H87)E9%-T&UL M4$L! A0#% @ -GE&2ED0>XM' @ 60L T ( !?FH M 'AL+W-T>6QE49*"5*AT](" !9% #P M @ 'P; >&PO=V]R:V)O;VLN>&UL4$L! A0#% @ -GE& M2E6@+.EL 0 'Q, !H ( ![V\ 'AL+U]R96QS+W=OSB( 0 U!, !, M ( !DW$ %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& "< )P"# )"@ 3', end XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 70 117 1 false 26 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.aviragentherapeutics.com/20161231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Company Overview Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-1-company-overview Note 1 - Company Overview Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Basis of Presentation Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-2-basis-of-presentation- Note 2 - Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Fair Value Measurements Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-3-fair-value-measurements Note 3 - Fair Value Measurements Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Accrued and Other Current Liabilities Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-4-accrued-and-other-current-liabilities Note 4 - Accrued and Other Current Liabilities Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Liabilities Related to Sale of Future Royalties Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-5-liabilities-related-to-sale-of-future-royalties Note 5 - Liabilities Related to Sale of Future Royalties Notes 11 false false R12.htm 011 - Document - Note 6 - Net Loss Per Share Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-6-net-loss-per-share Note 6 - Net Loss Per Share Uncategorized 12 false false R13.htm 012 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-7-licenses-royalty-collaborative-and-contractual-arrangements Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements Uncategorized 13 false false R14.htm 013 - Disclosure - Note 8 - Share-based Compensation Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-8-sharebased-compensation Note 8 - Share-based Compensation Uncategorized 14 false false R15.htm 014 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 15 false false R16.htm 015 - Disclosure - Note 3 - Fair Value Measurements (Tables) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-3-fair-value-measurements-tables Note 3 - Fair Value Measurements (Tables) Uncategorized 16 false false R17.htm 016 - Disclosure - Note 4 - Accrued and Other Current Liabilities (Tables) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-4-accrued-and-other-current-liabilities-tables Note 4 - Accrued and Other Current Liabilities (Tables) Uncategorized 17 false false R18.htm 017 - Disclosure - Note 5 - Liabilities Related to Sale of Future Royalties (Tables) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-5-liabilities-related-to-sale-of-future-royalties-tables Note 5 - Liabilities Related to Sale of Future Royalties (Tables) Uncategorized 18 false false R19.htm 018 - Disclosure - Note 6 - Net Loss Per Share (Tables) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-6-net-loss-per-share-tables Note 6 - Net Loss Per Share (Tables) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Tables) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-7-licenses-royalty-collaborative-and-contractual-arrangements-tables Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-3-fair-value-measurements-details-textual Note 3 - Fair Value Measurements (Details Textual) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 3 - Fair Value Measurements - Summary of Investments (Details) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-3-fair-value-measurements-summary-of-investments-details Note 3 - Fair Value Measurements - Summary of Investments (Details) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 3 - Fair Value Measurements - Unrealized Gain (Loss) on Investments (Details) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-3-fair-value-measurements-unrealized-gain-loss-on-investments-details Note 3 - Fair Value Measurements - Unrealized Gain (Loss) on Investments (Details) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 4 - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-4-accrued-and-other-current-liabilities-summary-of-accrued-and-other-current-liabilities-details Note 4 - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 5 - Liabilities Related to Sale of Future Royalties (Details Textual) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-5-liabilities-related-to-sale-of-future-royalties-details-textual Note 5 - Liabilities Related to Sale of Future Royalties (Details Textual) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 5 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-5-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details Note 5 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 6 - Net Loss Per Share - Computation of Historical Basic and Diluted Net Loss Per Share (Details) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-6-net-loss-per-share-computation-of-historical-basic-and-diluted-net-loss-per-share-details Note 6 - Net Loss Per Share - Computation of Historical Basic and Diluted Net Loss Per Share (Details) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Details Textual) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-7-licenses-royalty-collaborative-and-contractual-arrangements-details-textual Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Details Textual) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements - Components of Revenues From Royalties, Collaborative and Contractual Agreements (Details) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-7-licenses-royalty-collaborative-and-contractual-arrangements-components-of-revenues-from-royalties-collaborative-and-contractual-agreements-details Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements - Components of Revenues From Royalties, Collaborative and Contractual Agreements (Details) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 8 - Share-based Compensation (Details Textual) Sheet http://www.aviragentherapeutics.com/20161231/role/statement-note-8-sharebased-compensation-details-textual Note 8 - Share-based Compensation (Details Textual) Uncategorized 30 false false All Reports Book All Reports avir-20161231.xml avir-20161231.xsd avir-20161231_cal.xml avir-20161231_def.xml avir-20161231_lab.xml avir-20161231_pre.xml true true ZIP 47 0001437749-17-001767-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-17-001767-xbrl.zip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ə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ɬ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
E\\1%N,-/TY"%[=0L[$6](^*OM M5^S((LJ< R&M#=;)!A.&)G]^_F%N*$30:&.C"MK^V%(\P24FM,WT*0-UR=\, MSM4DZ8^@WW!XH3YC!'>? ?D=IN<9BN2S24[L*^2\N$"^KY#3*[-?;S[A+20H MK^#"#*V0;=T?X5VJN?F;-KT%5]J6H O!_2D:I10 MW<+-]1E7T%&'Y%3JJBO!2;UYHJ,NNA)DTD/$P!QS)>BD!TPS5<65/ C=R:-T M1_07*AHC(+K*H"OW1#6GB:[;S97#:-@:AB,_A\:<-C3*;(*W23F;%N/4%'C\SJ0A3]'G)N3*9 MKC:3I'$G'3R&)_1,#O4C:*74##LC!LTR*-B\?.!)D5T@HK?Y@DC)U!7!"TAI MGFAZ#C4E$32RF21QQO8[O(/[JL?:OXUV.PM/ ?$58#K7Y(UL_D(^9&R9:1\R MGJ15/9)3UL-8*1#.C=5I-@8:J/.NG"WGZ! M[CHS2Z"_@*Z%@K=&&Y':++?FQQ04U[P#"4 A#.@*PI3>:V_%G<(.ZX\:CC.: MXJ.-^!ZX\BC.4$JOP(XK#DJ?BX38BN,HY^<:AC#> D%V,EK(JRT9M M[5Q=C(O\?F/(2 ;GN&/I9U1OM8HWX3DQ-:9?UBJ M>OP_I[=5V5FQ$XVE$&Q%+Q-P6J&P>4A5V.#^"MW:JJIF(Q%)ODC'%0-_SHUB MKJL;6!5"6WO0:F-!%(R6MY"L^1V-O;TKDD!":J&.?(4+^0*04%K*,*B="[+L M FF#X86XVGLCE8J-A-(*VQMFB^Y?44*%Z:UC;1FTM"$6?R8JW5TE@.TH*.)G M4^ZCKSR.^$P>=1/[[RU4G"1,4XO#6"2.?D.?@]-$A!4F*=_Y'^[D"+-9)*0^ M> M^=2KZ:1>C2EYQB#:X0H@$4VEG^C-(%B]W98LQ.9=43FBWCB:)M+B)6ZR_&6-M$>E!5)\=X\J!I+> M=$-2KBPA#7EKSFI9Q,65#=<8&9UL1E<6DQDXRBB=*YJ=&2PZ*39.:71F\)C< M))CVM#$^FEZ*@J3'C2:"7$.GE!Z^.@F8_1X]\WJCJRYP,1) M?_T=52.?.=K9R:X@I'G[5I+)ZLH!I7Z<7IDEYDWS M9D5&!^#$4GW1P23KYT7; =C7*LHY&(R#7IUE]DO.'SMS'XH2GWT/DXS]D.=L M[SE]D'"^V!]"5Y#D+X#/UCQ$\ 3&7OJV<(/O"3\?^ \J$%5*.T'6K98C?<+0 MQV+Y:++_A'JB[-O$GRG<#]JW@.U:&G\GX\5=;? W 'IE]A\P7J[8=C#;0J[W M?SCS1;E)Y!L&G6%O7?A;%_[619N(DD3%[#%I*OV M7K@2;VD&2*U3H;] RQ@AZ<&9UV-@9JS;N):S31N7=\[B(G"#V8U5O0N2..27 MLVA \ XDZ8[930E;K/QQ;+8LZ"YB851_B>SL$B1 MF$<#CE;9'4^S4G2X)+#LKEF0:\PB6(J.C1^25F&U"\3_>?R2+U'J8Z[%MUT( 0;"*(_@!B\6H(^ M7RD<\V35"J*.60 K%;^B+$SGI'QY0^)&EY%:8[SZ:(@T\**DMU&DK)@] HZ? M?FV!P4>;GHC-6B(?B?.1N)<:B9N63W3"IZ4/\O@@CTHQP<8J@"NPJ,,]:HW. ME="7:HJH;"E7;HMHX2 VR%V9#L.&A4<^)WQ8V,Q3+#-XG%L@M4ATXQAS;OW( M9TVM-6\MG"!X?/&>(%?8^>\;+!+\C7;X+J7^$*-YDM*4Y5;N\G)=7: 4,C'3 MLAK?'.UO53TMP6S6:-*.]0"]L^YAV-6>BB1E#&/BNG+E-N6P-0UZG-'5S >5'YO(,YH-'1F(5N/PK61 [3G<+[0>#A51&[U)W4A M\Z9,A8<1OT/ M-M\EQ+Q7TMLLV#"M!.'Y@M^D)QSCZK^JX3")CX#RF= M0SD MR&:7SSGR.4?^8KG/(&@3"^[#='(%P8ZQL7V=?XS3K__P8G^3T<+]T5[APJ9F MA2M3M6]4FZ1%])"1]'.!+8)+GM?@UL3M+(WC966"-0TH]K"IVIR=#6"0@J@1 M=^YA[W0)P49A7E?6;E_343_CH[^*/Q9J)+6#L]N0V\LJI=0V?.W8,=,"CNI- M*9-PFBLJ>D?0=1F:Z^^TL;!'=H-OM]D:V@ [466M;;K7R]@K=>!X=--%,T;= MWSXYGL5LB%VWZ7N0F'Y_M621U!U3%+8W^3IH"S3,TR=VS MT:40:]<(\QHAKX,%B$FPS3E;LY63D?*V',W6:T!V_-9<7%&8FU4.;#N,I>I^ MW;#=S\-6;7G3*KC6#0"#7O7;LO&YRG*."?=@/U2;?2*X?H,Q"7'Z^)UI;5E. MZ]ZG'OH^6F53K*V*J$4[/.OG; GD6_>'W?V??XW9/D+"U>X2;F$B21HS:VQ1 MN NTR5*:CT:,SY4CX_GTEV8:-^K#QO6] M_>%WR\:6; 1B0MM,G[(C?XE)_$>N14EGFWY#G\K>*)4=D_3VL1-5^GNH&_B$ M=I\'_@+RP'LV8WSFN,\<-U?F<2?:C"O@210@W%S#< 4==1Z^2H%T)72M-T\T M? 2N **>&DV<#*Z@T\&>K')DN)(GURU4MOD-_\\=H)!]\O]02P$"% ,4 M" V>49*I@20SL)L [2@@ $0 @ $ 879I49*#]#A\XH+ @>@ $0 M @ 'Q; 879I49*T]') M?,$( !G; %0 @ &J> 879I&UL4$L! A0#% @ -GE&2G,FYH9V'P Y+H" !4 ( ! MGH$ &%V:7(M,C Q-C$R,S%?9&5F+GAM;%!+ 0(4 Q0 ( #9Y1DJYCD"- MCBP 'I3 @ 5 " 4>A !A=FER+3(P,38Q,C,Q7VQA8BYX M;6Q02P$"% ,4 " V>49*MDVY<*PA #L^P( %0 @ $( MS@ 879I&UL4$L%!@ & 8 B@$ .?O ! $! end